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ABSTRACT
Allodynia, an outcome of neural injury. is a condition in which non-painful
stimuli (e.g. light brushing or light touch of clothing) evoke pain. Unlike normal
(nociceptive) pain, allodynia is triggered by input from low-threshold (A13) afferent
fibers. Normally. the synaptic transmission of ~nput appears to be modulated by
glycine released from spinal intemeurons. Thus, the blockade of spinal glycine
receptors with intrathecal (i.t.) strychnine (STR) produces reversible. segmentally
localized allodynia in the rat; a condition blocked by the spinal administration of
excitatory amino acid (EM) receptor antagonists. These results suggest that, in
the absence of spinal glycinergic modulation. input from A13-fibersacquire access
to spinal pain-signalling pathways. If this hypothesis is correct. then Lt. STR-
induced allodynia should be blocked by antagonists of spinal NMDA-receptors. and
by neuromodulatory systems that modulate EM-mediated synaptic transmission
in the spinal cord . Therefore, the specific objectives of this study were to: 1)
determine the effect of Lt. AP-7 (NMDA-antagonist). cyclopentyladenosine (A1-
agonist ; CPA), CGS-21680 (~-agonist), muscim?1 (GABAA-agonist) and baclofen
(GABAe-agonist) on STR-allodynia; 2) compare the effect of intravenous mexiletine
on STR-allodynia and calibrated bilateral paw-pinch (without STR); 3) determine
the effect of intravenous milacemide (a glycine prodrug and substrate for MAO-B)
on STR-allodynia; and 4) test the sensitivity of this milacemide effect to
pretreatment with clorgyline (MAO-A inhibitor) or l-deprenyl (MAO-B inhibitor) .
Male, Sprague- Dawley rats, fitted with Lt. catheters , were lightly anesthetized with
urethane. Stlmelus-evoked changes in blood pressure and heart rate, and cortical
electroencephalographic (EEG) activity were continuously recorded. After Lt. STR
(40 J,Jg), repetitive brushing of the hair with a cotton tipped applicator (a normally
ineffective stimulus) evoked a marked and progressive increase in mean arterial
pressure (MAP) and heart rate (HR), an abrupt motor withdrawal (WD) response
and desynchronization of the EEG; effects comparable to those elicited by
intradermal mustard oil without STR. Pretreatment with Lt. AP-7, CPA, CGS and
muscimol, but not baclofen, dose-dependently inhibited STR-allodynia without
affecting EEG synchrony. The EDsoS for Lt. AP-7 were: 1.12 JJg for the evoked
change MAP, 1.71 JJg for the evoked change in HR, and 0.36 JJg for the evoked
changein withdrawal duration. The corresponding EDsoS ranged from 0.02-o.07I..1g
for CPA; 2.69-3.11 I..Ig for eGS and 0.44-0.51 I..Ig for muscimol. Intravenous
mexiletine inhibited the responses evoked by noxious paw-pinch (without STR) and
hair deflection in STR-treated rats with equal potency (EDsos=9-17 mglkg). There
was no concurr t change in EEG synchrony and no blockade of motor efferent
pathways. Intravenous milacemide inhibited STR-allodynia (EDsos =398-404
mg/kg) at doses having no effect on normal nociception. This selective anti-
allodynic effect was blocked by pretreatmentwith l-deprenyl, but not with clorgyline.
iii
The results of this study support the following conclusions. 1) Glycine is a selective
modulator of non-noxious somatosensory input in the spinal cord of the rat. 2) In
the presence of Lt.STR, lowthreshold afferent input accesses an NMDA-mediated
spinal sensit isation mechanism normally act ivated by high threshold (nociceptive)
fibers . 3) Systemic mexiletine inh ibits both abnormal (STR-allodynia) and normal
(noxious pinch) nociception at a common central site , most likely the dorsal hom
cells receiving convergent AI3- and C-fiber input. 4) The recruitment of
neuromodulatory systems utilizing spinal A1- and GAB~ -receptors blocks the
abnormal responses to hair deflection during STR blockade of spinal glycine
receptors. 5) Increasing central glycine concentration by means of a systemic
glycine prodrug (milacemide) norma lizes the spinal processing of low threshold
afferent input in STR-allodynia. 6) The spinal pharmacology of STR-allodynia is
sim ilar to that of clin ical allodynia, and clearly distinct from that of normal
nociception. 7) STR-allodynia is a rap id, selective and valid non-injury model for
investigating this abnormal pain state .
iv
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1 Introduction
1.1 Statement of the Research Problem
Injury to the peripheral or central nervous system can effect an abnormal
sensory state in which innocuous stimuli acquire the ability to evoke intense pain;
a condition known as anodynia. Clinically, allodynic pain is triggered by input from
low threshold mechanoreceptive primary afferent neurons (Meyer et al., 1985;
Campbell etaL , 1988; Price et aL, 1989; Treede et al., 1991); that is, by peripheral
(AP)substrates which normally have no role in pain transduction and transmission.
Although the pathophysiological mechanisms of allodynia are unknown, the striking
change in modality subserved by Al3-fibers after nerve injury , and the apparently
limited role of abnormally sensitized C-nociceptors in this condition (Cline et al. ,
1989) are highly suggestive of a central dysfunction.
Under normal conditions, the synaptic transmission of low threshold afferent
input appears to be modulated by glycine and GABA (y-aminobutyric acid) released
from intemeurons in the dorsal hom of the spinal cord (Curtis et al., 1968,1971;
Game and Lodge, 1975; Wilcockson et al., 1984; Todd, 1990; Todd and Sullivan,
1990). The loss of such inhibitory modulation, as might occur after nerve injury,
could enhance the synaptic efficacy between Al3-fibers and pain-signalling
pathways , thereby permitting the miscoding of low-threshold input as pain .
2Consistent with this central hypothesis of allodynia are reports that the intrathecal
(l.t.) injection of strychnine(STR; a competitive glycine receptor antagonist) into the
spinal subarachnoid space of rodents induces a pure allodynic state. Thus
innocuous hair deflection(HD) in the presence (but not absence) of i.t. STR evokes
behavioral, cardiovascular, neurochemical and electrophysiological responses
comparable to those elicited by noxious thermal, mechanical or chemical
stimulation without STR (Beyer et aI., 1985, 1988; Sosnowski and Yaksh, 1989;
Yaksh, 1989; Shermanand Loomis, 1994, 1995, 1996; Milne et aI., 1996; Sherman
et aI., 1996; Onaka et aI., 1996). Importantly, these tactile-evoked responses are
segmentally localized (Sherman and Loomis, 1995) and exhibit a spinal
pharmacology that is distinct from that of conventional nociception (Yaksh, 1989;
Sosnowski and Yaksh, 1989; Sherman and Loomis, 1994, 1995, 1996). Indeed,
glycine appears to be a selective modulator of non-nociceptive input in the rat
spinal cord as Lt. STR neither enhances nor inhibits responses to high threshold
cutaneous stimulation (Sherman and Loomis, 1996). Collectively these data
indicate that the acute blockade of spinal glycine receptors with Lt. STR yields an
abnormal sensory condition having many of the features of clinical allodynia .
Previous pharmacological studies have shown that STR-allodynia is dose-
dependently inhibitedby i.t. excitatory amino acid antagonists including NBQX (2,3-
dihydroxy-6-nitro-7-sulphamoyl-benzo(f) quinoxaline) and y-DGG (y-D-
glutamylglycine) and by Lt. glycine or betaine (N,N,N-trimethyl glycine) (Sherman
and Loomis, 1995, 1996) (see Table II, page 22) . In contrast, STR-allodynia is
insensitive to Lt. morphine, CP-96345 [neurokinin(NK)1-receptor antagonist] or
neonatal treatment with capsaicin, at doses which are effective against normal
nociception (Sherman and Loomis, 1994, 1996). These results indicate that the
spinal pharmacology of STR-allodynia is distinct from the nociception normally
conveyed by small diameter (A6 and C) fibers and evoked by high-threshold
thermal, chemical or mechanical stimuli (for review see Yaksh and Malmberg,
1994).
The spinal dorsal hom contains the first synaptic contacts between
peripheral afferent fibers and the central neurons conveying somatosensory
information to the critical sites in the brain. Insight into the spinal processing of
somatosensory input could reveal useful information about the mechanism(s) of
allodynia as well as identify modulatory systems that could be exploited
pharmacologically to offset the abnormal sensations triggered by light tactile input
in allodynia . The neural systems implicated in the spinal processing of Af3-input are
illustrated in Figure 1. To further investigate the, spinal pharmacology of STR-
allodynia, and to explore the neuromodulatory systems affecting low threshold
somatosensory input in the spinal cord, the present study sought to systematically
determine the effect of GABA, adenosine and glycine in the STR-model. Also, the
effect of mexiletine, AP-7 [D(-)-2-amino-7-phosphonoheptanoic acid; an NMDA-
receptor antagonist], and milacemide (a glycine prodrug) on STR-allodynia and
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Figure 1. Possible neurotransmitterslneuromodulators and their receptor
systems implicated in the spinal processing of low-threshold (A~ afferent
Input Glutamate (Glu), aspartate (Asp) and ATP are thought to be released from
the central tenninals of Al3-fibers. Normally, extracellular glutamate and aspartate
act on AMPA- and kainate-receptors. NMDA-receptors, although present on
second order neurons, are not normally reauited by low-threshold input (but may
be important in abnormal low-threshold input) . Local inhibitory systems modulating
the response to ~nput utilize GABA, glycine and adenosine. The latter, including
that derived from the extracellular hydrolysis of ATP, can act on ~- and/or 1\-
receptors . The postsynaptic effects of these neurotransmitters are well established.
The presynaptic effects of glycine and adenosine are less clear and have been
omitted for clarity. Although, in the present diagram, adenosine is shown to be
released from intemeurons, its neuronal origin is unclear.
normal nociception (without STR) was compared .
1.2 General Organisation of th Somatosensory System
Sensory systems consist d serial neural pathways linking the periphery with
the spinal cord, brain stem, thalamus and cerebral cortex. These pathways are
comprised of primary afferent fibers, second order neurons and the third order
neurons.
1.2.1 Primary Afferent Neurons
Primary afferent neurons carry somatosensory information from the periphery
to the spinal cord where they synapse with second order neurons located in the
dorsal grey matter. Thus, the first synapse in this neural circuitry is located
centrally in the outer laminae of the dorsal hom. Primary afferent fibers found in
mixed peripheral nerves are subdivided into three main types; A, Band C. A-fibers
are further divided into four sub-groups (a, 13, V and O) based on their diameter,
degree of myelination and corresponding conduction velocity (Table I). These
fibers selectively respond to different modalities in accordance with the types of
sensory receptors located on their peripheral terminals. Thus, AO-fibers are
activated primarily by intense mechanical pressure but can also be activated by
noxious thermal or chemical stimuli (Kandel and Schwartz. 1991). In contrast, C-
6Table I. Classification of fibers in peripheral nerves
Fiber
Type
Innervation Mean Diameter Mean Conduction Velocity
um (range) mlsec (range)
Aa Primary Muscle Spindle
To Skeletal Muscles
Cutaneous Touch and
Pressure Afferents
12 (12-20)
8 (5-15)
100 (70-120)
50 (30-70)
~ Mechanoreceptors, Nociceptors 3 (1-4)
Mechanoreceptors, Nociceptors 1 (0.5-1.5)
Sympathetic Postganglionic
B
C
Motor to Muscle Spindle
Sympathetic Preganglionic
6 (6-8)
3 (1-3)
20 (15-30)
15(12-30)
7 (3-15)
1 (0.5-2)
fibers are primarily activated by noxious chemical, mechanical and thermal stimuli.
Psychophysical studies in humans demonstrate that electrical stimulation of A~-
fibers evoke a brief pricking or stinging sensation while that evoked by C-fiber
stimulation is described as a prolonged burning and unpleasant (Torebjork and
Ochoa, 1980; Konietzny et aI., 1981). Stimulation of At3-fibersnormally evokes light
tactile sensations including vibration and mild pressure . These primary afferent
fibers enter the spinal cord through the dorsal root entry zone. Large diameter
fibers bifurcate centrally with one branch entering the dorsal columns and the
second branch penetrating deep into the neck of the dorsal horn where they
reverse course and terminate in the nucleus proprius (Figure 2). Small diameter
DorsalColumn
Afferentaxons
for pain
Figure 2. Cross section of spinal cord showing the termination of primary
afferent fibers in dorsal grey matter. Small diameter fibers terminate directly in
the outer laminae of the dorsal hom where they make synaptic contact with the
dendrites of second order neurons (I). Large diameter fibers bifurcate centrally with
one branch penetrating deep into the neck of the dorsal hom (II) where they reverse
course and terminate in the nucleus proprius, and the second branch entering the
dorsal columns (III).
fibers terminate directly in the outer laminae of the dorsal horn where they make
synaptic contact with the dendrites of second order spinothalamic tract neurons
(Figure 2) (Kandel and Schwartz, 1991).
1.2.2 Second Order Neurons
The primary afferent fibers form the synaptic contacts with second order
neurons in the dorsal horn. These are either relay cells, with axons projecting to
the brain stem or thalamus, or intemeurons that transfer information locally to other
interneurons or relay cells in the adjacent segments. Second order neurons are
classified into three general types (Besson and Chaouch, 1987; Henry, 1989): 1)
non-nociceptive (receiving input from large diameter myelinated fibers), 2)
nociceptive specific (those receiving input from C and A'6fibers), and 3) nociceptive
non-specific (those receiving convergent input from both nociceptive and non-
nociceptive primary afferent fibers). The latter are also known as wide dynamic
range (WDR) neurons. WDR neurons show a brisk transient response to low-
threshold mechanical stimuli and a delayed after-discharge in response to noxious
stimuli, the latter representing a slow depolarization of the neuron (Henry, 1989).
Virtually all sensory informationarising from the somatic segment of the body enters
the spinal cord through the dorsal root.
91.2.3 Excitatory Neurotransmitters and Neuromodulators in Somatosensory
processing in the Spinal Cord
A variety of substances present in primary sensory neurons have been
proposed as possible neurotransmitters or neuromodulators. Putative afferent
neurotransmitters include : substance P (SP), neurotensin, cholecystokinin,
vasoact ive intestinal peptide, calcitonin gene related peptide (CGRP), somatostatin,
glutamate, aspartate and adenosine triphosphate (ATP) (Besson and Chaouch,
1987; Henry, 1989; Yaksh and Malmberg, 1994). The precise role of many of these
substances has not been fully elucidated. Currently, glutamate and aspartate are
believed to be the main excitatory neurotransmitters released from all primary
afferent fibers (Kangrga and Randic, 1991; Dougherty et aI., 1992). In nociceptive
fibers, these excitatory amino acids (EMs) co-exist with neuropeptides including
CGRP and substance P (Battaglia and Rustioni, 1988). ATP has been implicated
in the transmission of information from large diameter primary afferent fibers . Its
involvement in nociception is also suggested by the depressant effects of
adenosine (the product of its hydrolysis) on nociceptive neurons (Henry, 1989) .
Synapses of primary afferent and second order neurons are subject to
extensive modulation by a number of endogenous systems (Yaksh and Malmberg,
1994). local inhibition is mediated by glycine, adenosine and GABA (Nagy and
Daddona, 1985; Sawynok and Sweeney, 1989; Yaksh and Malmberg, 1994) (see
sections 1.4.2, 1.7.1 and 1.7.2) . Endogenous opioids, such as enkephalin, are
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present in spinal interneurons and mediate the local inhibition of nociceptive input
(Yaksh and Malmberg, 1994). Nociceptive transmission is also subject to
descending inhibitory modulation originating from sites in the pons (e.g. locus
coeruleus) and medulla (Le. nucleus raphe magnus).
1.2.4 Ascending Neural Tracts Conveying Sensory Information
There are two main pathwaysconveying sensory information from the dorsal
hom to the brain: 1) the dorsal column-Ieminiscal system; and 2) the anterolateral
system. The dorsal column-Ieminiscal system conveys touch and vibration sense
and is generally characterized by a well defined localization of the stimulus source.
The anterolateral system is responsible for conveying pain, thermal sensations
including cold and warmth, crude touch and pressure sensations, tickle and itch
(Kandel and Schwartz, 1991).
Dorsal column medial leminiscal system: The dorsal column pathway relays
somatosensory information directly to the medulla. It is comprised of ascending
axons of the large diameter primary afferent fibers and axons of second order
neurons originating in the dorsal horn. These axons ascend ipsilateraly to the
caudal medulla where they synapse onto the cells in the dorsal column nuclei
(cuneate and gracile nuclei). Fibers leaving the dorsal column nuclei arch across
the midline where they collect into a discrete bundle (the medial lemniscus) and
ascend to the thalamus. From the thalamus, the somatosensory information is
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conveyed to the anterior parietal lobe by thalamo-cortical neurons.
Anterolateral system: This system is actually composed of two major pathways
distinguished by their sites of termination: the spinothalamic tract and the
spinoreticular tract. The spinothalamic tract originates principally from cells in
lamina I. This tractmediatesfast pain, relayed from the periphery to the spinal cord
by M-fibers. In contrast,the spinoreticular tract principally originates from cells in
lamina V. It transmitsboth nociceptive and non-nociceptive(AI3-,A~- and C-fibers)
information and hencecells of this tract are referred to as WDR nociceptors. This
tract is important in slow pain. Axons of spinoreticular tract cells end on neurons
in the reticular formationof the brain stem, which then relay information rostrally to
the thalamus and otherstructures in the diencephalon. The spinoreticular tract also
relays information to the mesencephalic periaqueductal gray, the region
surrounding the cerebral aqueduct.
It is evident fromthis brief description that the processing of somatosensory
information is complex,involving several parallel but discrete systems which extend
throughout the neuraxis. These systems utilize multiple neurotransmitters and
several levels of regulation (spinal, bulbar, thalamic and cortical). Thus, under
normal conditions, nociceptive and non-nociceptive sensory information is
transmitted through distinct neural circuits, thereby ensuring appropriate
interpretation of the sensory stimulus.
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1.3 Neuropathic Pain
1.3.1 General Features of Neuropathic Pain
Acute pain arising from tissue injury has an immediate onset, a short
duration, temporally coupled to stimulus exposure and is intimately related to
d1angesinduced by peripheral inflammation. Physiologically, it is thought to serve
an important protective function . In contrast, chronic pain usually has delayed
onset and persists long after the time normallyrequired for tissue repair. Intuitively,
chronic pain involves more complex events than those of normal nociception and
has no apparent biological usefulness. Alongwith tissue damage and inflammation,
d1ronicpain is often associated with neuropathology. This includes changes in the
eNS leading to an increased sensitivity of central neurons; a condition known as
central sensitization (Dray et aI., 1994).
Neuropathic pain is a chronic condition resulting from traumatic injury to or
pathologyof the central or peripheral nervoussystem. Phantom limb pain, multiple
sclerosis, central post stroke pain, neuropathies such as those of diabetic,
alcoholic, nutritional or traumatic origin, post herpetic neuralgia, trigeminal
neuralgia,and reflex sympathetic dystrophyare some examples of neuropathic pain
(Bovie et aI., 1989; Tasker, 1990; Portenoy et aI., 1990; Triggs and Beric, 1992;
Woolf, 1993). It is characterized by allodynia, hyperalgesia and spontaneous pain
(Price et aI., 1989, 1992; Bonica, 1990; Coderre et aI., 1993; Galer, 1995).
Spontaneous pain is 'pain felt in the absence of any apparent physiological
13
stimulus. Hyperalgesia is an exaggerated response to a normally painful stimulus
and allodynia is a condition in which pain is evoked by a normally non-painful
stimuli (e.g. touch, vibration) . Additional symptoms may include a partial loss of
sensitivity, and the spread of pain to uninjured tissue (referred pain) (Price et aI.,
1989,1992; Coderre et aI., 1993; Woolf, 1993; Rowbotham, 1995).
Unlike regular pain, neuropathic pain often takes weeks or months to
develop following the causative event (Tasker, 1990). For instance, in a group of
127 patients with spinal cord lesions, the onset of pain ranged from a month to
more than a year in 79% of the patients (Tasker et aI., 1992). Neuropathic pain is
commonly described by sufferers as a burning, twisting, ripping, tearing or sharp
lancinating type of pain (Price et aI., 1992; Woolf, 1993; Gonzales, 1995) and is
often unbearably intense. It is difficult to treat and symptoms may last indefinitely
(Merskey, 1986). Conventional analgesics like opioids and adjuvant drug therapy
such as tricyclic antidepressants, barbiturates or anticonvulsants are only partially
or temporarily effective (Bowsher, 1991; Triggs and Beric, 1992; Baron and Saguer,
1993).
The use of opioid analgesics in neuropathic pain is highly controversial
(Amer and Mayerson, 1988; Portenoy et aI., 1990; Rowbotham et aI., 1991; Kupers
et aI., 1991; Jadad et aI., 1992). For example, neuropathic pain following
amputation or nerve injury has been shown to be unresponsive to opioids (Arner
and Mayerson, 1988). In contrast, patients with malignant neuropathic pain have
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shown a shift to the right in the opioid dose-response curve such that an increase
in the dose will provide effective pain relief (Portenoy et aI., 1990). For patients
with a demonstrable sympathetic component (i.e. sympathetically maintained pain),
interruption of the sympathetic nervous system with local anaesthetics (Price et aI.,
1989), sympatholytic drugs or by surgery is the major treatment approach (Woolf,
1993).
Surgical intervention in the periphery is also controversial. Pain relief is
usually temporary, often ineffective and may, in some cases worsen the situation
(White and Sweet, 1969; Wirth and Rutherford, 1970; Noordenbos and Wall, 1981).
Neurolytic procedures or electrical stimulation of the dorsal column or the brain,
produce partial relief for intractable pain of spinal cord origin (Tasker et aI., 1992).
However, these procedures are appropriate only for patients with a severe disabling
pain that is refractory to all other treatments. Pain of this type is often associated
with a terminal disease and limited life expectancy (Woolf, 1993).
1.3.2 Pathophysiology of Neuropathic Pain
Peripheral nerve injury often leads to pathological changes including neural
degeneration, neuroma formation, and spontaneous activity in damaged nerve
fibers (Coderre et aI., 1993) . Structural changes within spinal cord, such as the
loss of dorsal horn interneurons (Kapadia and La Motte, 1987; Sugimoto et aI.,
1989), some of which contain GABA and glycine (Todd and Sullivan, 1990). and the
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abnormal rearrangement of afferent nerve processes have also been reported. The
latter include central sprouting of large afferent fibers from lamina III to lamina II of
the dorsal hom, and sprouting of sympathetic nerves into the dorsal root ganglia
(Woolf et aI., 1992; McLachlan et aI., 1993). Functionally, these changes could
result in either a reduction in the threshold of activation of nociceptors and/or an
increase in the excitability of the central neurons comprising the pain-signalling
pathways (e.g. -central sensitization-). Central sensitization is characterized by
increased spontaneous activity, decreased threshold of activation or increased
responsiveness to afferent input, prolonged after-discharge to repeated stimulation,
and an expansion of the receptive field of dorsal hom neurons. These changes
would explain, at least in part, the phenomena of hyperalgesia, allodynia and
spontaneous pain (Dubner, 1991; Coderre et aI., 1993; Woolf, 1993).
The mechanisms underlying the development and maintenance of
neuropathic pain are unclear . However, the peripheral substrates triggering
allodynia and hyperalgesia are known to be different. Hyperalgesia arises from a
decrease in the threshold of activation of nocicep.tive C-fibers (Shir and Seltzer,
1990; Cline et aI., 1989; Lee et aI., 1994). In contrast, allodynia is triggered by
input from low threshold Afl-fibers (Meyer et aI., 1985; Campbell et aI., 1988; Price
et aI., 1989; Treede et aI., 1991); that is, by peripheral substrates that normally
have no role in pain transduction and transmission. The striking changes in the
modality subserved by Afl-fibers after nerve injury are highly suggestive of a central
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dysfunction.
1.4 Allodynia
1.4.1 Role ofAp-fibers in Allodynia
Allodynia, a characteristic feature of neuropathic pain, is an abnormal
condition in whidllight tactile stimuli (Le. touch or the brush of clothing against the
skin) acquire the ability to evoke intense pain. As noted above, allodynic pain is
triggered by input from AI3-fibers , rather than abnormally sensitized C-fibers
(Campbell et al., 1988). Thus selective nerve block using ischemia or nerve
compression eliminated both allodynia in the area of nerve injury along with light
touch sensation in adjacent normal skin without affecting the temperature
discrimination in patients with neuropathic pain suggesting that both sensations
were mediated by AI3-fibers (Campbell et al., 1988; Koltzenburg et al., 1992).
Conversely, nerve block with local anesthetics, that affected A6- and C-fibers (as
demonstratedby absence of temperature sensibilio/ in those patients), but not AB-
fibers did not block allodynia (Campbell et al., 1988). In addition, response
latenciesfor touch evoked-pain on the affected side were nearly identical to those
for the same stimulus applied to the homologous area on the normal side. Both
latencieswere muchfaster than the latenciesfor the detection of pain in the normal
limb (Lindblom and Verrillo , 1979; Campbell et al., 1988). These results indicate
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that allodynic pain is evoked by afferent input conveyed by low threshold A~-fibers.
In support of this conclusion, high-frequency. low intensity electrical nerve
stimulation worsens allodynia , unlike the analgesic effect observed with regular
nociceptive pain (Price at al., 1992). Finally the selective destruction of C-fibers in
rats using neonatal treatment with capsaicin did not prevent the induction of
allodynia following chronic constriction of the sciatic nerve (Shir and Seltzer. 1990).
Rather, this treatment blocked the development of thermal hyperalgesia. Overall.
these data indicate that A~-fibers mediate alldoynia whereas. C- and A6-fibers
mediate thermal hyperalgesia.
Since under normal conditions, the activity in Af.!l-fibers is perceived
exclusively as touch, light pressure and vibration. the fundamental question arising
from the phenomenon of allodynia is how this same neural activity acquires ability
to evoke severe pain. One possibility is that inhibitory intemeurons normally
modulating the response of spinal neurons to low-threshold afferent input may
become dysfunctional after injury. Indeed. intemeurons containing GABA and
glycine are known to be vulnerable to ischemic and excitotoxic damage (Tureen,
1936; Davidoff et al., 1967; Sugimoto et aI., 1989, 1990). The functional loss of
such inhibition could result in an excessive activation of second order neurons by
low-threshold afferent input thereby strengthening the synaptic contact between
non-nociceptive fibers and pain-signalling pathways. Thus . ~-input could be
miscoded as pain.
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1.4.2 Role of Spinal Glycinergic Intemeurons In Allodynla
GABA and glycine are important in the spinal processing of innocuous tactile
information (Yaksh, 1989, 1993). Glycine-like immunoreactivity (-L1), as
demonstrated using glycine antisera, is found throughout the gray matter in the
spinal cord of the rat (Van den Pol and Grocs, 1988; Todd and Sullivan, 1990). In
the dorsal hom, glycine-L1 is present in laminae I-IV, but is most densely localized
in lamina III and IV (Todd and Sullivan, 1990). These results are consistent with the
presence of glycine receptor-L1at axodendritic and axosomatic synapses in laminae
I-III and at dendrodendritic synapses in lamina II (Mitchell et aI., 1993). Thus,
binding and immunocytochemical data indicate that glycine and its corresponding
receptors are localized in regions of the dorsal horn containing the central
terminations of low-threshold afferent fibers (laminae III-IV). Furthermore,
glycinergic neurons in laminae II and III of the rat spinal cord have been shown to
receive a major monosynaptic input from myelinated low threshold cutaneous
primary afferent fibers (Todd, 1990). Collectively, current anatomical evidence
supports the hypothesis that A~fibers activate local glycinergic interneurons in the
spinal dorsal horn.
Pharmacological data also substantiate the relevance of glycine to the
regulation of the behaviour generated by low-threshold afferent transmission. Light
tactile stimuli, typically eliciting no more than an orientation response in rats, evoke
overt pain-like behaviours following the blockade of spinal glycine receptors with
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Lt. STR (Yaksh, 1989). STR exhibits very high affinity ( Ka = 3-10 nM) for the
glycine receptor (Young and Synder. 1974; Zarbin et aI., 1981). This is distinct
from the glycine modulatorysite locatedon the NMDA-receptor complex. The latter
is insensitive to STR blockade. The data from STR-treated rats are in agreement
with studies of single unit activity in the trigeminal nucleus of the monkey.
Intravenous (i.v.) STR induced a marked facilitation of the response of WDR
neuronsto electrical stimulation of low-threshold mechanoreceptive afferent fibers
(Yokota et aI., 1979). Iontophoretic delivery of STR in the lumbar spinal cord of
cats diminished the inhibition phase otherwise observed following natural and
electrical stimulation of low-threshold afferent fibers (Game and Lodge, 1975).
Conversely, the iontophoretic delivery of glycine in the spinal dorsal hom
diminished the responsiveness of dorsal hom neurons to light tactile stimulation
(light touch/light pressure), decreased the size of their cutaneous receptive fields
in cats (Zieglgansberger and Hertz, 1971), and reduced the responses of
spinothalamictract neurons, includinglow-thresholdand WDR neurons,in monkeys
(Wilcockson et aI., 1984).
These observationssuggest that the encoding of low-threshold mechanical
stimuli as an innocuous event depends upon the presence of intrinsic glycinergic
inhibition in the spinal dorsal hom. Indeed, genetic variants, such as the Poll
Hereford calf (Gundlach et aI., 1988) and the spastic mouse (White and Heller,
1982) which exhibit up to a 10-fold decrease in STR binding in the spinal cord,
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display exaggerated sensitivity to even modest cutaneous stimulation. Consistent
with these animal data are clinical reports of pronounced hypersensitivity to light
touch in humans during STR intoxication (Arena, 1979). Thus, glycinergic
dysfunction in the spinal dorsal hom could be an important central abnormality in
the development of allodynia.
1.4.3 Strychnine-induced Allodynia
Further support for the role of spinal glycine in modulating low-threshold
input is provided by the observation that pharmacological blockade of spinal glycine
receptors with L1. STR induces a pure allodynia like state in the rat (Beyer et aI.,
1985, 1988; Yaksh, 1989). In the presence of STR, innocuous mechanical
stimulation such as HO evoked high pitched vocalisation, biting and scratching of
the stimulated dermatomes and vigorous organised escape behaviour (Yaksh,
1989). These evoked responses resemble the hyperaesthesia reported by humans
during the preconvulsive stages of STR intoxication (Arena, 1979). A striking
feature of these responses is that they could be reliably driven by HO applied to
circumscribed areas of the body surface. These corresponded to the dermatomes
innervated by spinal segments near the site of Lt. STR injection. Similar results
were obtained using lightly anaesthetized rats pretreated with i.1. STR.
Exaggerated autonomic and motor withdrawal responses to repeated HO,
comparable to those evoked by noxious stimuli in the absence of STR, were
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reported (yaksh, 1989; Sherman and Loomis , 1994) . All HD-evoked responses
were observed without convulsions or seizure-like effects and thus did not reflect
a general sensitization of spinal neurons by Lt. STR. Subsequent studies in our
laboratory have shown that Lt. STR neither enhances nor inhibits responses to
noxious bilateral hind paw-pinch or tail immersion in water at 55°C. These results
indicate that: a) glycine is a selective modulator of non-nociceptive input in the rat
spinal cord; b) the blockade of spinal glycinergic receptors with i.t. STR yields an
abnormal sensory condition resembling allodynia; and c) Lt. STR has neither a
hyperalgesic nor an antinociceptive effect on normal nociception.
1.4.4 Spinal Pharmacology of Intrathecal Strychnine-induced Allodynia
Clinical studies have shown that allodynic pain is triggered by input from low
threshold (non-nociceptive) fibers . Therefore, any valid experimental model of
allodynia should exhibit a pharmacology that is distinct from that of normal (C-fiber
mediated) nociception. Previous studies of the STR model support this distinction
(Table II). For example, chronic treatment of neonatal rats with sub-cutaneous
(s.c.) capsaicin at doses that selectively destroyed C-fibers by adulthood and
yielded significant antinociception in the paw-pinch (mechanical), tail immersion
(thermal) and topical xylene (chemical) tests , had no effect on STR-allodynia
(Sherman and Loomis, 1996). Similarly, pain-like responses evoked by HD in STR-
treated rats were insensitive to antinociceptive doses of Lt.morphine and CP-96345
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Table II. Comparison of the spinal pharmacology of l.t. strychnine-allodynia
and normal nociception (without strychnine)
Treatrnentx Strychnine- Noxious References
allodynia stimulation
Agents affecting C-fibers
Sherman & Loomis, 199<4Morphine +
Capsaicin + Sherman & Loomis, 1996
CP-96345 + unpublished observations
(NK1-antagonist)
Glycine or analogue
Betaine + Sherman & Loomis, 1995
Glycine + Sherman & Loomis, 1995
Excitatory amino acids
y-DGG + + Sherman & Loomis, 1996
Nassb'Om et al., 1992
NBQX + +8 Sherman & Loomis, 1996
Nassb'Om et al., 1992
'+' -t blocks; '-' -t no effect
* All drugs were administered as a single i.t. injection except capsaicin which
was given as repeated s.c. injections during the neonatal period.
a The non-NMDA receptor antagonist CNQX was used instead of NBQX by
Nasstr6m et aI., 1992. I
(a NK1-feceptor antagonist) (Sherman and Loomis, 1994; unpublished observation).
In contrast, Lt. glycine and betaine selectively inhibited STR-allodynia, although
their effect on normal nociception was not systematically determined (Beyer et aI.,
1985, Sherman and Loomis, 1995). These results demonstrate that agents which
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selectively interfere with the function of C-fibers do not attenuate STR-allodynia in
the rat.
Glutamate and aspartate are the principal excitatory neurotransmitters in the
CNS (Mayer and Westbrook, 1987; Evans, 1989; Perschak and Cuenod, 1990),
and are released from central terminals of both low- and high-threshold afferent
fibers of rats and monkeys (Skilling et aI., 1988; Liu et aI., 1989; Kangrga and
Randic, 1991; Sorkin et aI., 1992). Indeed, glutamate-L1 and aspartate-L1 are
localized in the dorsal root ganglion (DRG) cells of both large- and small-diameter
primary afferent fibers (Wanaka et aI., 1987; Battalgia and Rustioni, 1988;
Westlund et aI., 1989, 1990), as well as in interneurons of the dorsal horn of cats,
rats and monkeys (Rizzoli, 1968; Fagg and Foster, 1983; Cottman et aI., 1987;
Storm-Mathisen and Ottersen, 1987). The intraspinal boutons of cat afferent hair
follicle fibers, labelled intra-axonally with horseradish peroxidase, are also enriched
with L-glutamate-L1 (Maxwell et aI., 1993). Consistent with the localization and
release of EMs from both low- and high-threshold afferent fibers, and their putative
role in somatosensory transmission, EAA recept~r antagonists have been shown
to block the excitation of spinothalamic tract neurons by noxious thermal,
mechanical, chemical and electrical stimuli in monkeys (Dougherty et aI., 1992),
and to dose-dependently inhibit STR-allodynia in lightly anesthetized and conscious
rats (Table II; Yaksh, 1989, Sherman and Loomis, 1994, 1996). Considering the
selective effect of Lt. STR on low-threshold afferent input in the spinal cord
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(Sherman and Loomis, 1996), and the marked sensitivity of this input to EAA
antagonists (Table II), it is possible that the blockade of spinal glycinergic
modulation by i.t. STR permits the exaggerated depolarization of second order
neurons in pain-signalling pathways by low threshold (AJ3) input, and the miscoding
of this input as pain.
1.5 Role of Excitatory Amino Acid Receptors in Sensory Processing
The biological actions of EMs are mediated by at least three subtypes of
ionotropic receptors. These receptor subtypes were identified on the basis of their
selective responsiveness to the following agonists; a-amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA), kainate (KA) and N-methyl-D-aspartate (NMDA)
(Watkings et aI., 1990). Collectively, the AMPA and kainate receptor subtypes are
referred to as non-NMDA receptors. While glutamate activates both NMDA and
non-NMDA receptors, aspartate is thought to act preferentially at NMDA-receptors
(Mayer and Westbrook, 1987; Dickenson, 1990). Non-NMDA receptor-coupled ion
channels mediate the fast component of the excitatory post synaptic potential
(EPSP). Under physiological conditions, NMDA receptor-coupled ion channels are
normally blocked by Mg2+ in a voltage-dependent manner. The opening of these
channels requires a prior depolarising potential, generated primarily by non-NMDA
receptors (for review see Ascher and Nowak, 1987). As a result of this prerequisite
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event for activation, NMDA receptors mediate the slow-romponent of the EPSP
(Headly and Griller, 1990; Watkins et aI., 1990) .
Intracellular studies using a hemisected rat spinal cord-hind limb preparation
demonstrated that the amplitude and duration of the EPSPs elicited by low-intensity
(touch; Af3) or high-intensity (pinch; AfJ and C) mechanical stimuli are blocked by
non-NMDA receptor antagonist, CNQX and the cell firing of the dorsal hom cells
was completely abolished (King and Lopez-Garcia, 1993). In contrast, the NMDA
receptor-antagonist, AP-5 (D-aminophosphonovalerate), blocked only the longer
latency spikes elicited by high-intensity cutaneous mechanical stimuli. It never
abolished the cell firing produced by such stimuli (King and Lopez-Garcia, 1993)
and was ineffective against responses evoked by light touch (King and Lopez-
Garcia, 1993). Thus, EAAsreleased from ~bers selectively activate non-NMDA
receptors under physiological conditions. In this regard Lt.y-DGG (non-selective
EM-antagonist), and NBQX (a selective AMPA-antagonist) have been shown to
block STR-allodynia in lightly anaesthetized rats (Sherman and Loomis, 1994,
1996); observations consistent with the model of ~ynaptic transmission illustrated
in Figure 1.
The role of spinal NMDA receptors in normal nociceptive transmission has
been extensively investigated. If a brief noxious stimulus, sufficient to activate C-
fibers, is repeated at frequency ~O.3 Hz, the long latency discharge recorded in
second order neurons progressively increases in magnitude; a phenomenon called
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''wind up" (Mendell, 1966; Price, 1978) . 'W ind up' is a characteristic feature of C-
fiber evoked nociception and is mediated by EAAs acting at post-synaptic NMDA-
receptors (Dickenson and Sullivan, 1987). In rats, NMDA receptor antagonists such
as ketamine, AP-5, dextromethorphan and levorphanol have been shown to block
the slow temporal summation of EPSPs evoked by electrical stimulation of C-
afferent fibers ('wind up') without reducing the response of these same neurons to
A-fiber stimulation (Davies and Lodge, 1987; Dickenson and Sullivan, 1987;
Dickenson et aI., 1991). Psychophysical studies in humans have also shown that
second pain, a physiological correlate of long-latency C afferent-evoked impulses,
is sensitive to NMDA-receptor blockade by dextromethorphan (Price et aI., 1994) .
This phenomenon is believed to underlie the development of central sensitization
during sustained nociceptive input (Le. inflammation). Thus, 'wind up' is a
physiological process mediated by NMDA receptors and is normally restricted to
noxious (C-fiber) afferent input.
It has recently been suggested that under pathophysiological conditions, AB
afferent impulses may acquire access to the same 'wind up' mechanism, thereby
allowing low-threshold fibers to trigger pain (Price et aI., 1989; 1994a) . Unlike
normal subjects, patients with nerve injury exhibit temporal summation to repeated
activation of AB afferents at frequencies ~O.3 Hz, using either natural stimuli such
as stroking the skin with a gauze pad or low-threshold electrical stimulation (Price
et aI., 1989). Subjects reported that the pain evoked by these normally innocuous
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stimuli had the same burning quality and tendency to radiate as noxious heat
evoked pain. Moreover, subanesthetic doses of ketamine (an NMDA-receptor
antagonist) attenuated the pain evoked by low-threshold mechanical stimulation in
patients with traumatic spinal cord injury, post-herpetic neuralgia, post-stroke pain
and peripheral nerve injury (Backonja et aI., 1994; Eide et aI., 1994, 1995).
Collectively, these observations suggest that a process similar to 'wind up' is
activated in allodynia and that this process is sensitive to NMDA-receptor blockade.
If, in the presence of Lt. STR, low threshold (A~) input acquires access to the same
sensitization ('wind up') mechanism normally activated by C-fiber input, then STR-
induced allodynia should be blocked by NMDA-receptor antagonists. While NMDA
receptor antagonists are known to attenuate tactile-evoked agitation in conscious
STR-treated rats (Yaksh, 1989), their dose response effects in the anesthetized
STR model have not been determined.
1.6 Effects of Local Anaesthetics on Normal Nociception and Neuropathic
Pain
Local anaesthetics such as mexiletine, lidocaine and tocainide are known to
be effective in the treatment of clinical and experimental neuropathic pain, including
allodynia. This includes the treatment of pain arising from peripheral nerve injury,
chronic painful diabetic neuropathy, trigeminal neuralgia, causalgia and other
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chronic pain syndromes which are resistant to conventional drug therapy (Lindstrom
and lindblom, 1987; Dejgard et aI., 1988; Chabal et al., 1992; Colclough et aI.,
1993). Indeed, a sustained analgesic response has been reported weeks after the
termination of infusion in humans (Edward et al., 1985, Steinhaus and Howland,
1958; Kastrup et al., 1986). Systemic mexiletine has also been shown to relieve
chronic allodynia-like symptoms in rats with ischemic spinal cord injury (Xu et al.,
1992) or spinal nerve ligation (Chaplan et aI., 1995).
The pharmacological effect of local anaesthetics is normally associated with
frequency- and voltage-dependent blockade of Na+channels. resulting in the nerve
conduction block. However, the analgesic effect in patients with neuropathic pain
is unlikely to result from simple peripheral conduction block. Local anaesthetics do
not block nerve conduction when given systemically in clinically effective analgesic
doses (Dejgard et aI., 1988; Chabal et al., 1989; Rowbotham et aI., 1991).
Electrophysiological studies have shown that sub-anesthetic doses of lidocaine and
tocainide significantly suppress C-fiber evoked polysynaptic responses of spinal
neurons, incompletely reduce reflex activity in ha"1string flexor a-motoneurons, and
completely blocked reflexes to noxious chemical and thermal stimuli in normal rats
(Woolf and Wiesenfeld-Hallin, 1985; DeJong et al., 1969; Dohi et aI., 1979). C-
fiber evoked 'wind up' is also blocked by Lt. lidocaine in the rat (Fraser et aI., 1992).
In vitro, subanesthetic concentrations of lidocaine inhibited direct and synaptically
driven NMDA- and neurokinin-receptor mediated post-synaptic depolarizations in
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rat spinal neurons (Nagy and Woolf, 1996) . These results indicate that under
physiological conditions sub-anesthetic doses of local anesthetics selective block
C fiber-evoked activity in the spinal cord .
Mexiletine, an orally active congener of lidocaine, is the most commonly
used local anesthetic for clinical neuropathic pain (Hegarty and Portenoy, 1994)
and should be effective in any valid experimental model of allodynia . Moreover, if
AB-input acquires access to pain signalling-pathways in the spinal cord, then
mexiletine should block both the AB-evoked responses (in presence of STR) and
C-fiber evoked responses (without STR) with comparable potency.
1.7 Inhibitory Modulation in Sensory Processing
1.7.1 Role of Spinal Adenosine
There is a growing body of evidence implicating the role of purines in the
spinal modulation of afferent neurotransmission (Sawynok et aI., 1986, Delander
and Hopkins, 1986). Adenosine , a probable purin rgic agonist, is thought to exert
its effect at specific purine receptor sites. These receptors are G-protein coupled
and are classified on the basis of their ability to inhibit (A,-receptor) or stimulate (Az-
receptor) adenylate cyclase through Gi and Gs proteins, respectively (Van Calker
et aI., 1979; Marala and Mustafa 1993; Jockers et aI., 1994). A1-agonists such as
LPIA [N6_ (L-2-phenylisopropyl)-adenosine] or cyclohexyladenosine in the dose
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range of 0.5 - 10 ~g. and non-selective (A1/A~ agonists like NECA [5'-(N-ethyl
carboxamido)-adenosine] or 2-chloroadenosine in the dose range of 0.5 - 3.6I-1g.
produced potent analgesia in the tail flick and hot plate tests following Lt.
administration (Sawynok et aI., 1986; Delander and Hopkins, 1986). Conversely,
Lt. adenosine receptor antagonists such as theophylline (11.8 ~g) and 8-
phenyltheophylline (0.12 ~g) attenuated adenosine-induced antinociception
(Sawynok et aI., 1986; Delander and Hopkins. 1986). Such pharmacological
studies have consistently implicated A1- . rather than"; -receptors in the spinal
modulation of nociceptive input (Fastbom et aI., 1990; Karlsten et al., 1991; Poon
and Sawynok, 1995; Lee and Yaksh, 1996).
That adenosine affects A13-evoked responses was first demonstrated by
Salter and Henry (1987). They observed that the depressant effect of vibration.
applied to the ipsilateral hind limb. on nociceptive (wide dynamic range) neurons
in the cat dorsal horn was potentiated by an adenosine uptake inhibitor
(dipyridamole. 1.2 mglkg. i.v.). This inhibitory effect was reversed by caffeine (20
-60 mglkg, i.v.), and unaffected by naloxone (0.1 - 0.4 mglkg. i.v.). They proposed
that the analgesic effect of vibration in the spinal cord is mediated primarily by
purines and may underlie the mechanism of action of transcutaneous electrical
nerve stimulation (TENS) in clinical pain management. as predicted by the gate
control theory (Melzack and Wall, 1965). TENS activates large diameter primary
afferent neurons and produces analgesia in the area affected by such stimulation.
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Conversely, in the inherited nervous system disorder known as the lesh-Nyhan
syndrome, affected children show involuntary movements and self-injurious
behaviour (e.g. biting of lips and fingers). Patients with this syndrome are known to
lack the enzyme, hypoxanthine-guanine phosphoribosyl transferase, thereby
reducing the plasma concentration of adenosine. Vv'hetherthere is a corresponding
decrease in the CNS concentration of adenosine is unknown but caffeine does
worsen this syndrome (Stone, 1981).
Based on these experimental and dinical observations, adenosine has been
used in the management of neuropathic pain. The effect of systemic adenosine on
pain symptoms in seven patients with peripheral neuropathy was evaluated in
double-blind, placebo-eontrolled cross-over study (Balfrage et aI., 1995).
Adenosine (50 IJglkglmin, i.v.) reduced spontaneous pain, allodynia and
hyperalgesia whereas placebo had no effect. In other case reports, adenosine (70
lJg/kglmin, i.v.) or R-PIA (191Jg,i.t.) alleviated spontaneous pain and touch-evoked
allodynia in patients with peripheral neuropathy (Karlsten and Gordh, 1995; Sollevi
et aI., 1995) . low dose adenosine (70 IJglkg/mjn, i.v.) has also been shown to
effect analgesia in awake healthy volunteers subjected to experimentally-induced
ischemic pain (Segerdhal et aI., 1994) .
Similar results have been obtained from studies using animal models of
neuropathic pain. Yamamoto and Yaksh (1991) reported antinociception in thermal
hyperalgesia with Lt. NECA (0.01 - 0.3 nmol) in rats subjected to chronic nerve
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constriction injury (Bennet and Xie, 1988). Intrathecal R-PIA (10 ng) and NECA (5
ng) reduced the pain-like behaviours induced by Lt. prostaglandin F2a in mice
(Minami et aI., 1992). LPIA or NECA, in the range of 0.3-1 nmol i.t., dose-
dependently inhibited touch-evoked agitation in conscious STR-treated rats
(Sosnowski and Yaksh, 1989). Both drugs were equi-potent in STR model and
were significantly blocked by i.p. caffeine . The potent inhibitory effect of these
adenosine analogues occurred at doses that were only mildly antinociceptive in the
hot plate test (Sosnowski and Yaksh, 1989). These results demonstrate the
remarkable sensitivity of abnormal pain states to adenosine or related agonists, in
both injury and non-injury model of neuropathic pain. However, the receptor
subtypes (A1 versus ~) mediating the anti-allodynic effect of adenosine have not
been systematically investigated.
1.7.2 Role of Spinal GABA
GABA is densely localized in the spinal cord (Sivilotti and Nistri, 1991;
Bohlhalter et aI., 1994) where it appears to modulate both nociceptive and non-
nociceptive neurotransmission. In case of nociception, GABAA-agonists such as
muscimol and GABAe-agonist like baclofen given Lt. in dose range of 0.1-1 I-Ig,
significantly increased the response latency in the tail flick and hot plate tests, and
vocalization threshold to tail shock in the rat (Roberts et aI., 1986; Hammond and
Drawer, 1984; Wilson and Yaksh, 1978). Intrathecal baclofen and muscimol (0.3 -
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flinch response to formaline injection (s.c) in a dose-dependent manner (Diring and
Yaksh, 1995). Although these studies did not report any motor dysfunction at
anti nociceptive dosests 1~g, i.t.), comparable doses of muscimol and baclofen
(~1~g, i.t.) produce muscle flaccidity in rats (Hammond and Drower, 1984, Diring
and Yaksh, 1995). Conversely, GAB~-receptor antagonists such as picrotoxin
(0.25 ~g) and bicuculline (1 ~g) decreased nociceptive threshold in the tail-shock
and tail-flick tests (Roberts et aI., 1986). The i.t. administration of CGP 35348 (30
~) or phadophen (100 ~g) (GABAg-antagonists) also blocked the antinociceptive
effects of glutamate micro-injected into the ventromedial medulla of monkeys
(McGowan and Hammond, 1993). These pharmacological data are supported by
electrophysiological studies demonstrating the inhibition of glutamate- and pinch-
evoked activity by GABA, ionophoretically applied onto spinothalamic tract cells in
monkeys (Willcockson et aI., 1984). In vitro studies using rat spinal cord
preparation have shown that A6-afferent fibers activate GABAergic interneurons
which inhibited nearby dorsal hom neurons (yoshimura and Nishi, 1995). Bath
application of musicmol and baclofen also depressed excitatory synaptic
transmission (Kangrga et aI., 1991; Araki, 1994). Thus, both GABAAand GAB~
receptors in the spinal cord appear to mediate the antinociceptive effects of
exogenously administered GABA agents.
GABA has also been implicated in the spinal modulation of low-threshold
afferent input. Thus, Lt. bicuculline (30 1J9) (GABAA-antagonist) induced an
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allodynia-like state in the rat similar to that produced by Lt. STR (Yaksh , 1989).
Systemic administration of baclofen (0.1 mglkg , i.p.), but not muscimol (1mglkg ,
l.p.), inhibited allodynia-like behaviours arising 1-4 days after focal spinal cord
ischemia in the rat (Hao et al.. 1992) . Thus , spinal GABA, specifically GABAA-
receptors appears to modulate Al3 transmission in a manner similar to spinal glycine
in normal conditions (absence of neural injury); however , in the presence of neural
injury, spinal GABAe-receptors seem to playa major role in the modulation.
Consistent with this hypothesis is the observation that GABA and glyc ine are
co-Iocalized in interneurons in lamina I-III of the dorsal hom (Mitchell et aI., 1993).
In fact glycine immunoreactivity in lamina I-III is virtually restricted to neurons that
also exhibit GABA immunoreact ivity (Todd and Sullivan, 1990) suggesting that the
effects of GABA and glycine on synaptic transmission may be complementary. The
receptors mediating the distinct effects of glycine and GABA are co-localized on the
same post -synaptic membrane (Mitchell et aI., 1993; Todd et aI., 1996) . Finally ,
these GABAA- and glycine-receptors are separately coupled to chloride ion
channels leading to increased chloride conductance and neuronal
hyperpolarisation.
Recent electrophysiological studies in the rat spinal cord slices have
demonstrated that evoked inhibitory post synaptic potentials (IPSP's) consist of two
distinct components; a short-duration and long-durat ion IPSP. Bath application of
STR and bicuculline blocked the short- and long-IPSP, respectively. These results
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suggest that the short IPSP's are mediated by glycine acting at STR-sensitive sites,
while the 10ng-IPSP's are mediated by GABA acting at GABAA-receptors
(Yoshimura and Nishi, 1995). The time course of GABA- and glycine-mediated
IPSP's in this study are similar to those previously recorded in motoneurons of cats
(Rudomin et aI., 1990). If glycine and GABA are released together into the synapse
upon stimulation. and if GABA and glycine effect distinct but complementary
inhibition of Al3-input in the spinal cord. then the allodynia arising from the blockade
of spinal glycine receptors should be attenuated by the concurrent activation of
GABA,.-, but not GABAe-receptors.
1.7.3 Role ofSpinal Glycine
The importance of glycine in the processing of AB input has been extensively
discussed (see section 1.4.2). Thus. the disinhibition of spinal glycine by Lt. STR
(a competitive glycine antagonist). produces an allodynia-like state in rats. similar
to that seen in patients with neuropathic pain. Consistent with the role of STR-
sensitive glycine receptors in the dysesthetic state is the observation that glycine
and betaine (a glycine analogue) inhibited STR-induced allodynia in lightly
anesthtized rats (Sherman and Loomis. 1994). However. the charged nature of
these molecules at physiological pH required that they be injected directly into the
subarachnoid space.
Milacemide (2~-pentylaminoacetamide)is an orally active glycine pro-drug.
36
Serum milacemide rapidly enters and equilibrates with the CNS compartment where
it is metabolised primarily by MAO-B to glycinamide (Christophe et al., 1983, De
Varebeke et al., 1989) and finally to glycine (see Figure 3). Milacemide (100, 200,
400 mglkg i.p.) dose-dependently increased the concentrations of glycine and
glycinamide (intermediary metabolite) in the cerebrospinal fluid (CSF) of the rat
(Semba et al., 1993) and remained significantly elevated 7h after administration
(400 mglkg, i.p.) (Semba and Patsalos, 1993; Semba et al., 1993). Serum glycine
concentration were unaffected. Clinical studies have confirmed the anticonvulsant,
mood elevating, cognitive and memory enhancing properties of milacemide (Van
Dorsser et al., 1983; Houtkooper et al., 1986; Saletu et al., 1986; Handelman et al.,
1989; Schwartz et al., 1992). In view of the ability of systemic milacemide to
increase central glycine concentration (Semba et aL, 1993), and given the locus
and mechanism of action of STR-allodynia, milacemide is an obvious candidate for
testing in the STR model.
1.8 Rationale and Specific Research Objectives
Allodynia, a symptom of clinical neuropathic pain, is a condition in which
normally non-nociceptive tactile stimuli acquire the ability to evoke excruciating
pain. Although, the neuropathology is unclear, changes in the spinal processing
of low-threshold afferent input are strongly suggested. Under normal conditions,
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MAo-a
MILACEMIDE~ GLYCINAMIDE~ GLYCINE
~I 4,,-------,1 1 = BBB = I =
~ MILACEMIDE MAo-a~ GLYCINAMIDE~ GLYCINE
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Figure 3. Systemic milacemide readily crosses blood-brain-ba"ier (BBB)
where it is converted to glycine by the action ofmonoamine oxidase-B (MAO-
B). Milacemide rapidly equilibrates between blood and brain. As a substrate for
MAO-B, milacemide is first metabolised to glycinamide and subsequently converted
to glycine. Milacemide is metabolised primarily in the central rather than the
peripheral compartment. While some glycinamide produced in the periphery can
cross the blood brain barrier. its contribution to the central concentration is small.
(Adapted from Semba et aI., 1993)
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the synaptic transmission of mechanoreceptive A13-fibers is modulated by glycine-
containing interneurons in the substantia gelatinosa. Consistent with the concept
of a central dysfunction in allodynia is the observation that Lt. STR, (competitive
glycine antagonist) produces reversible allodynia in both conscious and lightly
anesthetized rats.
Pharmacological studies have shown that STR-allodynia is insensitive to
conventional analgesics (morphine, capsaicin and NK1-antagonist), but is dose-
dependently reversed by Lt. glycine and betaine. The latter have no effect on
normal nociception at anti-allodynic doses. Thus, STR-allodynia exhibits a spinal
pharmacology that is distinct from normal nociception, is qualitatively similar to that
of clinical allodynia, and may represent a useful non-injury model for the
investigation of allodynia. To further investigate the spinal pharmacology of STR-
allodynia and to explore the neuromodulatory systems affecting the spinal
processing of A13 transmission (Figure 1), the aim of the present study was to
investigate the role of spinal NMDA-, adenosine-, GABA-, and glycine-receptors in
lightly anesthetized STR-treated rats.
The specific objectives of this study were:
1. To determine the effect of Lt. AP-7 (an NMDA-receptor antagonist) on STR-
induced allodynia.
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2. To compare the effect of i.v. mexiletine on STR-induced allodynia and
normal nociception (without STR).
3. To compare the effect of Lt. cyclopentyladenosine (A1-agonist) and CGS-
21680 (~-agonist) on STR-induced allodynia and to determine the
sensitivity of their respective effects to pretreatment with Lt. DPCPX (A1-
antagonist).
4. To compare the effect of Lt. muscimol (GABAA-agonist) and baclofen
(GABAa-agonist) on STR-induced allodynia.
5. To compare the effect of i.v. milacemide (a glycine pro-drug) on STR-
induced allodynia and normal nociception (without STR) and to determine
the sensitivity of this effect to pretreatment with clorgyline or l-deprenyl.
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2 Methods
2.1 Animals
Male, Sprague-Dawleyrats (260 - 490 g at the time of the experiments) were
obtained from the Vivarium, Animal Care Services, Memorial University of
Newfoundland (St. John's, Canada). Animals were housed in the Animal Care
Facility, with a 12-h darkllight cycle (lights on 07:00 h), a room temperature of 22°C,
and free access to rat chow and tap water . All experiments were conducted in
accordance with the guidelines of the Canadian Council on Animal Care and were
approved by the Memorial University Animal Care Committee.
2.2 Implantation of Intrathecal Catheters
Anesthesia was induced with 4% halothane (Halocarbon Laboratories, River
Edge, USA) in oxygen and maintained at a concentration of 2.0 - 2.5 %. Rats were
fitted with i.t. catheters prepared from stretched polyethylene tubing (PE-10) pulled
to ::::1.5 x the original length (Shennan and Loomis,,1994). The catheters were filled
with sterile saline (Astra Pharma Inc., Mississauga , Canada), inserted through the
cisterna magna into the spinal subarachnoid space, and guided 8.5 em caudally
terminating near the L1-L2 segment. A fixed loop near the rostral end of the
catheter was sutured to the overlying muscle to secure the catheter and the incision
closed . The rostral tip was externalised on the top of the head and sealed with a
41
stainless steel plug . Animals with Lt. catheters were then housed individually and
permitted to recover for at least 4 days . Only those animals exhibiting normal
feeding, drinking and grooming behavior, and having normal gait were used for
experimentation.
2.3 Acute Anaesthetized Animal Preparation
On the day of the experiment. animals were anesthetized with halothane and
the left jugular vein was cannulated. Thereafter, halothane was gradually
discontinued and anesthesia was maintained using i.v, urethane (10% wlw in
saline, Sigma Chemical Inc., St. Louis, USA). The initial dose of 1.1 glkg was
administered slowly over 10-15 min as the anesthetic effect of halothane declined.
Body temperature was maintained at 3rC with a thermostatically-regulated blanket
(Harvard Instruments, Sl Laurent, Canada). The left carotid artery was cannulated
for continuous monitoring of blood pressure and heart rate using a pressure
transducer (P23XL) and polygraph (Model 79E, G~ass Instruments, Quincy USA).
The trachea was also cannulated and the animal was allowed to breathe
spontaneously. The incision was then closed and the animal was positioned in a
stereotaxic apparatus (Narishige, Tokyo, Japan) with the head firmly secured using
ear bars. The incision and the contact points with the ear bars were coated with 2°"
lidocaine gel (Astra Pharma, Inc.) to reduce the basal sensory input. Cortical EEG
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was monitored using 2 subcutaneous needle electrodes (E2, Grass instruments)
placed 2 mm left of midline, one extending rostrally entering the skin near bregma,
the other extending caudally and entering the skin about 2 mm caudal to the first.
The animal was then permitted to stabilize for one hour. During this time,
anaesthesia was adjusted with i.v, urethane as required.
To ensure reproducible touch-evoked responses in STR-treated rats, a light
level of anaesthesia is required (Sherman and Loomis, 1994). A reliable correlation
has been observed between the proportion of time that the EEG is "synchronized"
and the depth of urethane anaesthesia (Angel et aI., 1976; Lincoln et aI., 1980).
For our purposes, light anaesthesia was defined as the presence of an EEG pattern
which fluctuates between high amplitude ("synchronized") and low amplitude
("desynchronized") activity , with high amplitude activity present for not more than
60% of the time . The basis for this cut off in the STR model has been reported
previously (Sherman and Loomis, 1994). The level of anaesthesia was also
assessed by observing the animal's reflex responses to stimulation.
2.4 Application of Stimuli
The innocuous tactile stimulus was applied in the form of hair deflection
(HD) . The hair on the legs, flanks and lower back was sequentially brushed with
a cotton-tipped applicator using an oscillating motion (rate of 1-2 per sec; 2-min
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stimulus train applied at 5-min intervals). Oscillating stimuli elicit cardiovascular,
motor and neurochemical responses in this model more effectively than stationary
ones (yaksh, 1989; Sherman and loomis, 1994; Milne et aI., 1996). Brushing was
donewithno more force than required to move the applicator through the hair (hair
deflection) suchthat only the pelage was disturbed. In the absence of spinal STR,
this stimulus produced no change in heart rate (HR) or blood pressure (BP) and
was not associated with any type of motor withdrawal response. After Lt. STR (40
~g), the same stimulus applied to the affected dermatomes elicited a 15-20 mm Hg
increase in mean arterial pressure (MAP), a 15-20 beats/min (bpm) increase in HR,
and an abrupt motor withdrawal response (see results).
Noxious mechanical stimulation was performed using bilateral hind paw
pinch . Both paws were gripped with hemostats at the post axial border (on the
medial surface, distal to the tarsal joint) such that the region of skin covered by
each hemostat was ",20 mrrr'. The force of the pinch was produced by 500 g
weights attached to the handles of each hemostat. This resulted in a final pressure
on each paw of approximately 0.7 kPa. Withdrawal of the hind paws was prevented
until the end of the 10-second stimulus period . In some experiments, noxious
chemical stimulation was applied in the form of a s.c. injection (0.05 ml) of 50%
mustard oil in each of the hind paws .
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2.5 Drug Administration
AP-7 [(+/-)-2-amino-7-phosphonoheptanoic acid], N8~yclopentyladenosine
(CPA), CGS-21680 hydrochloride [2-p-(2carboxyethyl)phenylethylamino-5'-N-
ethylcarboxamidoadenosine HCI; CGS]. DPCPX (1,3-dipropyl-8-
cyclopentylxanthine), muscimol hydrobromide, R(+)-baclofen hydrochloride, and
dorgyline hydrochloride were obtained from Research Biochemicals International
(Natick, USA). Mexiletine hydrochloride [1-methyl-2-(2,6-xylyloxy)-ethylamine
hydrochloride; Boehringer Ingelheim Inc., Ingelheim am Rhein, Germany] and
milacemide (2-N-pentylamino acetamide; Searl Inc., Skoki, USA) were generously
provided by their manufacturers. Tyramine hydrochloride and l-deprenyl
hydrochloride were obtained from Aldrich Chemical Company Inc. (Milwaukee,
USA). Mustard oil was obtained from Madison, Colman and Bell (East Rutherford,
USA).
All drugs were dissolved in 0.9% saline (Astra Pharma, Inc.) except CGS-
21680, which was dissolved in a 0.02 M solution of sodium hydroxide (Fisher
Scientific Company, Ottawa, Canada),and DPCPX whichwas dissolved in dimethyl
sulfoxide (DMSO; British Drug House, Toronto, Canada). Mustard oil was diluted
with an equal volume of 90% alcohol (Fisher Scientific Inc.). Strychnine
hemisulphate (Sigma Chemical Company) was administered Lt. in a volume of 4 ~I
to reduce the rostro-caudal spread in the CSF. All other Lt. injections were made
in a volume of 5 ~1. Intravenous injections were made in a volume not exceeding
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0.5 ml, and i.p. injections were made in volume of 1 ml. Drug solutions were
flushed through l.t and i.v catheter using 10 ~I and 1 ml sterile saline, respectively.
2.6 Experimental Protocols
2.6.1 Control Experiment (i.t. vehicle R.t. STR)
To establish the control responses to STR + HD (in absence of any drug
treatment), each rat received Lt. vehicle followed 10 min later by Lt. STR (40 ~g)
(Figure 4A). This dose of STR elicits optimal allodynia without convulsive activity
in lightly anesthetized rats (Sherman and Loomis, 1994). The HD stimulus (2-min
duration) was applied at 5-min intervals after vehicle and strychnine injection
(Figure 4A). These stimulus trains were repeated until no HD-evoked
cardiovascular or motor withdrawal responses were observed (-30 min after STR).
2.6.2 Quantification of Strychnine-induced Allodynia
The HD-EVOKED MAXIMUM increase in blood pressure and heart rate
within 30 min of i.t. STR was used for graphical and statistical analysis (see section
2.8) . The total period of time following STR injection, during which a motor
withdrawal responses could be evoked by HD was also determined. In order to
verify that each animal was maintained at an appropriate level of anaesthesia (less
than 60% synchrony in the EEG) throughout the experiment, the % synchrony was
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A. I.t. vehicle / strychnine control (STR control)
Lt. Vehicle
(5 Ill)
I IHD
o 5
u.sra
(40pg)
I IHD
10 15
IHD
30 ....... min
B. General protocol for dose-response experiments
Lt.Drug u srn
Smcontrol (1STdose) (40pg)
I I IHD IHD IHD
60 75 80 85 90 ....... min
I.t. Drug Lt.STR
(~Ddose) (40pg)
I I IHD IHD IHD IHD IHD
180 195 200 205 210 215 220 ....... min
Figure 4. Summary of the Strychnine (STR) control protocol (A) and dose-
response protocols (B). All time scales are in minutes. Each hair deflection
stimulus (HD) was applied for 2-min using a cotton tip applicator. Following Lt. STR
(40 ~g), the HD stimulus was repeated every 5 min until the STR effects were no
longer detected (- 30 min) (A, B). One dose of Lt. AP-7, CPA, CGS, muscimol or
baclofen was administered 15 min before Lt. STR (B; upper panel). The second
dose was administered approximately two hours after the first dose (B; lower panel).
Preliminary time-course experiments indicated that a 15-min pretreatment period
yielded optimal pharmacological activity for Lt. administration (A).
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calculated by determining the number of 1-min intervals with a synchronous EEG
(determined visually) and expressing this as percentage of the experimental time.
2.8.3 Dose-response analysis for intrathecally administered drugs
For dose-responsestudies of Lt. AP-7, CPA, CGS, muscimol and baclofen,
control responses to STR + HD were first determined in the absence of any drug
treatment (see Figure 4A). Approximately one hour later, one dose of the above
mentioned drugs was administered Lt. This was followed 15 min later by Lt. STR
(40 ~). Hair deflectionwas then applied at 5-min intervals as described previously
(Figure 48). All animals received multiple drug doses. The order of dosing was
from low to high to reduce the possibility of a carry over effect and thus, the
recovery time. No more than three doses were administered to the same animal,
and no animal received any further drug treatment once the highest dose had been
given. Preliminary time-course experiments indicated that a 15-min pretreatment
time was optimal for Lt. drug administration and that 1.5 hr between doses was
sufficient for complete recovery from even th~ highest doses. Therefore,
subsequent doses were generally given approximately two hours after the previous
dose (lower panel of Figure 48). For AP-7, mexiletine and CPA dose-response
studies, the Lt. vehicie/STR control was repeated after each dose to verify complete
recovery from the previous dose, and to ensure the reproducibility of STR-allodynia
throughout the experiment. For the remaining dose-response experiments, Lt.
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vehicle'STR control responses were determined once at the onset of the
experiment. All animals were killed with an overdose of urethane at the end of the
experiment.
2.6.4 DPCPX Experiments
The selectivity of Lt. adenosine agonists for A1- and ~ -receptors were
determined in a separate group of animals. Control responses to STR + HD were
initially established (see Figure 4A). Approximately one hour later, rats were
pretreated with Lt. DPCPX (10 IJg)followed 10 min later by Lt. CPA (0.2IJg) or CGS
(5 IJg). STR was administered 15 min after CPA or CGS, and STR-allodynia was
quantified as described in section 2.6.2. The effect of CPA (0.2 IJg) or CGS (5 IJg)
alone (no DPCPX) on STR allodynia was also established. Thus, each rat was in
all of the following protocols:
Lt. DMSO (151J1)' i.t STR (40 IJg) (STR control)
I.t. DPCPX (10 IJg)' Lt. CPA (0.2 IJg)' Lt. STR
Lt. DPCPX (10 IJg) 'i.t. CGS (5IJg)' Lt. STR
Lt. CPA (0.2 IJg) , Lt. STR
Lt. CGS (51J9)' i.t. STR
A 1.5-hour recovery period was allowed between protocols (sufficient for the STR-
responses to return to the control values). The dose of DPCPX (10 IJg) used in this
study was selected on the basis of preliminary experiments.
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2.6.5 Mexi/etine Experiments
Control responses to HD were determined 5 min after the Lt. injection of
saline (151-11, Figure 4A). Ten minutes later, STR (40 I-Ig)was injected Lt. and the
HD stimulus was applied at 5-min intervals (Lt. vehicle I STR control, Figure 4A)
until all sensory-evoked responses were no longer detectable (-30 min after the
STR injection). Approximately 1 h after the first STR injection. control responses
to calibrated paw pinch were determined . Animals were then injected with
mexiletine(5 or 15 mg/kg i.v., infused slowly over 10 min) and calibrated paw pinch
was repeated 5 min after termination of the infusion. When the responses to
noxiouspinch had normalized (about 1-2 min), Lt. STR (40 1J9)was injected and the
HD was applied at 5-min intervals for 30 min. Most animals received 2 doses of t.v.
mexiletine. Animals were allowed to recover for 2 h after the first mexiletine-STR
treatment. Before a second dose of mexiletine (15 or 30 mglkg i.v.) was given, the
STR control was repeated to verify recovery from the initial mexiletine effect, as
evidenced by a complete return of the STR control responses.
2.7 Protocols for Mi/acemide
To establish the time course of activity for each dose of milacemide in STR-
model, milacemide(100,400 or 600 mg/kg) was injected Lv. and the effect on STR-
induced allodynia was followed for four hours. These doses and the 4-h time period
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were chosen on the basis of preliminary experiments.
2.7.1 Dose-response Study
The general protocol for the dose-response experiments is shown in Figure
5(A). At the onset of the experiment, i.t. vehiclelSTR control responses were
obtained as described previously (sections 2.6.1-2; Figure 4A). One hour later, one
dose of milacemide (100, 400, 600 mglkg) was slowly infused i.v, over periods of
10 (for 100 mglkg) -30 min (for 400 and 600 mglkg) . Every hour thereafter, Lt. STR
(40 ~) was injected and the responses to HD were determined as described above
(sections 2.6.1-2). Due to the short duration of allodynia «30 min), STR was
administered every hour for four hours. Animals were killed with an overdose of
urethane at the end of the experiment.
2.7.2 Comparison of the Effect of Milacemide on Strychnine-allodynia and
Mechanical Nociception
To compare the effect of milacemide (600 mglkg) on STR-allodynia and
mechanical nociception (without STR), HD-evoked responses in presence of Lt.
STR (40 IJg), and calibrated bilateral hind paw-pinch in absence of STR were
determined every hour for four hours following milacemide administration (Figure
58). Control responses to Lt. vehicle/STR were initially determined (Figure 4A).
Approximately one hour later (after the first STR effect had completely abated)
A. Milacemide dose-response protocol
milacemide i.t. STR i.t. STR i.t. STR i.t. STR
STRcontrol (i.v.) (40/19) (40/19) (40/19) (40/19)
I I I HO's I HO's I HO's I HO's
o 60 120 180 240 300 min
B. Effect of milacemide on paw-pinch (PP) and STR-allodynia
milacemide Lt.STR Lt.STR Lt.STR Lt.STR
STRcontrol (600mg/kg, Lv.) (40/1g) (40/1g) (40/1g) (40/1g)
Ippl ppf HO's pp 1HO's pp fHO's pp~ ~
o 55 60 120 180 240 300 ....... min
C. Effect of MAO-A or -B inhibitor
i.p. clorgyline/ milacemide Lt.STR Lt.STR i.t. STR I.t. STR
STRcontrol l-deprenyl (600mg/kg, i.v.) (40/1g) (40/1g) (40/1g) (40/1g) Tyramine (I.v.)
I I IHO's I HO's I HO's IHO's
o 60 180 240 300 360 420 460....... min
Figure 6. Summary of protocols for the mllacemlde experiments. All time scales are in minutes .
Each hair deflection (HD) stimulus was applied for 2-min using cotton tip applicator (see section 2.4).
Following Lt. strychnine (STR; 40 1-19), the HD stimulus was repeated every 5 min until the STR effects
were no longer detected (- 30 min) (A, B, C). Hind paw-pinch (PP) was applied bilaterally, for 10 sec (B)
using calibrated hemostats. STR was injected every hour for four hours following milacemide infusion .
Tyramine was given approximately 40 min after the last STR-injection (C).
O'l
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control responses to calibrated paw-pinch were determined. Animals were then
injected with milacemide (600 mgIkg i.v.• infused slowly over 30 min) . STR (40 ~g,
i.t) was injected every hour for four hours following the termination of infusion. Hair
deflection was applied for 2-min every 5-min interval up to 30 min after each STR
injection. Paw-pinch was applied once every hour for four hours following
milacemide; this was done 5 min before each Lt. STR injection (Figure 5B) .
2.7.3 Clorgyline nd L-Deprenyl Experiments
The general protocol for assessing the effects of c10rgyline or l-deprenyl on
the action of i.v. milacemide is shown in Figure SC. Intrathecal vehiclelSTR control
responses were initially determined (Figure 4A). Approximately one hour later . rats
were pretreated with c10rgyline(10 mglkg, i.p.; Semba et aI., 1993; de Varebeke et
aI., 1988) or l-deprenyl (3 mglkg, ip .: de Varebeke et aI., 1988; Semba et al., 1993)
(Figure 5C). Two hours later, milacemide (600 mglkg, LV.)was infused over a
period of 30 min. ~eafter, HD~voked responses in the presence of Lt. STR (40
~) were determined every hour for fOtI hours . In ~ separate group of animals, the
effect of c10rgylineor l-deprenyl on STR-allodynia (no milacemide) was determined
every hour for four hours . To assess the selectivity of inhibition of clorgyline and
l-deprenyl for MAO-A and MAO-B, respectively, i.v, tyraminewas injected at the end
of the experiment (Figure 5C). Doses ranged from 6.7 to 20 mg/kg and
cardiovascular responses were recorded.
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2.8 Data Analysis
All cardiovascular data are presented as the maximum change in MAP (=
systolic blood pressure + 1/3 pulse pressure) and HR evoked by the different
sensory stimuli. The change in MAP or HR was determined relative to the
immediate (1 min) pre-stimulus control period (not relative to T=O). The maximum
of each of these evoked responses, observed within 30 min of Lt. STR, was used
for graphical and statistical analysis. For the paw-pinch stimulus, the baseline MAP
and HR averaged over 1-min interval preceding stimulus application, was
subtracted from the maximum response evoked by the stimulus, and this difference
was reported.
With the exception of milacemide, all dose-response data were analysed
using regression ANOVA A modified t-testwas used to determine if the regression
lines had significant slopes (=1). Variability associated with single measurements
is indicated by the standard error of the mean (S.E.M.), while variability associated
with blocks of data is indicated by the pooled 95% confidence interval (CI). EDso
and 95% CI values were determined for all dose-response curves (Figure 7,10-13,
15, 17). The milacemide time-course data and dose-response data were analysed
using one-way ANOVA; significant differences were identified using the Neuman-
Keuls test (Figure16, 17, 19). Statistically significant differences among multiple
independent treatment groups (i.e. DPCPX experiments) were also determined
using completely randomised one-way ANOVA followed by the Neuman-Keuls test
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(Figure 14). The unpaired, two-tailed students t-test was used to the compare the
differences between two groups (Figure 18). Methods of data analysis were based
on a general text (Tallarida and Murray, 1987) .
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3 Results
3.1 General Observations Following Intrathecal Strychnine
Stroking the hair on the legs, flanks, and lower back of the lightly
anesthetized animal with a cotton tip applicator was without effect in Lt. saline-
treated animals (Figure 6A). An identical stimulus applied to rats pretreated with
Lt. STR (40 IJg)evoked a progressive rise in HR and 8P that persisted beyond the
duration of the HD stimulus (Figure 68). These responses were accompanied by
an abrupt scratching response near the site of stimulation and/or motor withdrawal,
as well as desynchrony of the EEG (Figure 68). Normalization of the EEG (return
to a synchronous pattern), which occurred 2-3 min after the discontinuation of the
HD stimulus, coincided with recovery of baseline 8P and HR. These cardiovascular
and motor responses were only evoked by HD at discrete sites corresponding to
dermatomes innervated by spinal segments near the site of STR injection. The time
course of these tactile-evoked cardiovascular responses were comparable to those
elicited by the intradermal injection of mustard oil into the hind paw (without STR)
and were greater in magnitude (Figure 6C). Average control responses to HD in
STR-treated rats were 10-15 mm Hg for MAP, 20-25 beats/min for HR and a
duration of 15-20 min during which motor withdrawal responses which could be
evoked by HD. These appear as the solid horizontal line in each of the dose-
response curves (e.g. Figure 7A-C). The STR effects lasted for approximately 30
min with the peak evoked cardiovascular responses appearing 5 min after Lt. STR
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Figure 6. Sample polygraph tracings of arterial blood pressure, heart rate,
and cortical EEG illustrating the effect of non-noxious hair deflection in
intrathecal (i.t) salin. and strychnine-treated rats. Hair deflection (HD) to the
legs, flank and lower back 5 min after the Lt. injection of saline had little effect on
blood pressure, heart rate or EEG (A). The same stimulus applied 5 min after Lt.
strychnine (40 1J9)evoked a marked and sustained increase in blood pressure and
heart rate, and desynchrony of the EEG (8). These evoked responses were
localized to dermatomes affected by the Lt. injection of strychnine, and observed
without convulsions or spontaneous motor movements. Each large deflection on
the time scale (upper trace) indicates 1 min and the horizontal bar below the time
trace indicates the application of the HD stimulus. For comparative purposes, the
responses evoked by the intradermal injection of mustard oil are shown (C). The
heart rate tracing is enlarged for clarity at the bottom of the figure . Arrows indicate
the Lt. injection of saline (A), the Lt. injection of strychnine (8) or the intradermal
injection of mustard oil into the hind paws (C).
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(data not shown).
3.2 Effect ofAP-7 on Strychnine-allodynia
Pretreatment with Lt.AP-7 ( 0.2, 1, 5 I-Ig)produced a dose-dependent reduction of
all HD-evoked cardiovascularand motor withdrawal responses in STR-treated rats
(Figure 7A-e). The corresponding E0soS and 95% Cis of AP-7 are summarised in
Table III. The E0soS ranged from 0.36 - 1.71 I-Ig. The % synchrony of the EEG
remained unchanged after AP-7 injection, regardless of the dose (Figure 70).
Baseline HR and arterial blood pressure were also unaffected by AP-7 (data not
shown). To compare the spinal effect of AP-7 on STR-allodynia and normal
nociception, rats pretreated with Lt. AP-7 received calibrated bilateral hind paw
pinch (Without STR). A dose of Lt.AP-7 (5 \-19) effecting almost complete blockade
of STR-allodynia had no effect on the responses evoked by noxious paw-pinch
(Figure 8).
Table III. ED~ and 95% C.I. ofAP-7 '
Treatment
AP-7 i.t."
Response
MAP
HR
WO
EOso(I-Ig) 95% CI
1.12 0.69 -1 .82
1.71 0.50 - 5.98
0.36 0.07 - 2.00
- AP-7 was injected 15 min before STR.
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Figure 1. Intrathecal AP-1 dose-dependently suppresses intrathecal
strychnine(STR)-allodynia. Following a 15-min pretreatment with Lt. AP-7,
responses to hair deflection (HD) were determined in the presence of i.t STR (40
~g). The HD-evoked increase in mean arterial pressure (M.A.P.; A), heart rate (8),
the duration for which withdrawal response could be evoked (C) and the %
synchrony in the EEG (0) are shown . Each point represents mean ± S.E.M. of 4-6
animals. Least squares regression lines and the corresponding 95% CI (dotted
lines) are shown . The horizontal solid lines and adjacent dotted lines indicate the
mean ± 95% CI of all STR treatments (N = 14-16) before AP-7.
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Figure 8. Sample polygraph tracings ofarterial bloodpressure, heart rate and
cortical EEG illustrating the effect of intrathecal AP-7 on strychnine-allodynia
(A) and noxious mechanical hindpaw-pinch (B) in the rat. AP-7 (5 ~g, i.t.) was
injected 15 min before the i.t. injection of strychnine (40 ~g). The arrow indicates
the injection of strychnine (A). Hair deflection (HD) was applied to the legs, flanks
andlower back of the rat 5 min after strychnine. Note the complete blockade of all
HD-evoked responses by AP-7 in the strychnine-treated rat. However, identical
dose of AP-7 failed to block the noxious paw-pinch evoked responses (B). Each
large deflection on the time scale (upper trace) indicates 1 min and the horizontal
bar below the time trace indicates the application of stimulus.
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3.3 Effect of Afexiletine on Strychnine-allodynia and Normal Nociception
Intravenous mexiletine (5,15 and 30 mglkg), administered 5 min before Lt.
STR, dose-dependently inhibited all the indices of STR-allodynia with EO~
ranging from 13.3 -16.6 mglkg (Table IV, upper panel of Figure 9, Figure 10A-C).
At 30 mg/kg, there was a small but non-significant increase in 0-' synchrony
compared to STR-control (Figure 100). Nevertheless, this increase was well below
the previously established cut-off of 60% synchrony (Sherman and Loomis, 1994).
The i.v. injection of mexiletine produced an immediate dose-dependent decrease
in baseline BP and HR (Le. before STR-allodynia). Baseline blood pressure
decreased by 10 mm Hg (5 mglkg) to 20 mm Hg (30 mglkg); an effect which lasted
for approximately 1-2 min. In all cases, blood pressure returned to normal before
Lt. STR was injected (data not shown). Baseline HR, which decreased by 30 bpm
(5 mg/kg) to 60 bpm (30 mglkg), was fully recovered 5 min after the injection of
mexiletine (5 mglkg). At higher doses, baseline HR remained partially depressed
(-4% of pre-injection values for 15 mglkg and -8% for 30 mglkg) throughout the
STR treatment.
The effect of i.v, mexiletinewas also determined against noxious paw-pinch
using the same experimental animals. Calibrated bilateral hind paw pi'!ch was
applied 3 min before the injectionof Lt. STR. Mexiletinedose-dependently inhibited
pinch-evoked cardiovascular responses (Figure 11A-B), and prevented
desynchrony of the EEG (Figure 9, lower panel) . All rats receiving 15 mglkg dose
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Figure 9. Sample polygraph tracings of arterial blood pressure, heart rate,
and cortical EEG illustrating the effect of intravenous mexi/etine on
strychnine-allodynia (A) and noxious mechanical hind paw pinch (B) in the
rat. Mexiletine (30 mglkg, i.v.) was injected 5 min before the i.t. injection of
strychnine (40 ~g). The arrow indicates the injection of strychnine (A). Hair
deflection (HD) was applied to the legs, flanks and lower back of the rat 5 min after
strychnine. Note the complete blockade of all hair deflection (HD)-evoked
responses by mexiletine in the strychnine-treated rat (A) and its inhibitory effect
against calibrated bilateral hind paw-pinch without strychnine in the same animal
(8). Each large deflection on the time scale (upper trace) indicates 1 min and the
horizontal bar below the time trace indicates the application of stimulus.
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Figure 10. Intravenous mexiletine dose-dependently suppresses intrathecal
strychnine(STR)-allodynia. Following a 5-min pretreatment with i.v. mexiletine,
responses to hair deflection (HO) were determined in the presence of Lt. STR (40
~g). The HO-evoked increase in mean arterial pressure (M.A.P.; A), heart rate (8),
the duration for which withdrawal response could be evoked (C) and the %
synchrony in the EEG (0) are shown. Each point represents mean ± S.E.M. of 4-7
animals. Least squares regression lines and the corresponding 95% CI (dotted
lines) are shown. The horizontal solid lines and adjacent dotted lines indicate the
mean ± 95% CI of all STR treatments (N=16) before mexiletine.
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Figure 11. Intravenous mexiletine dose-dependently suppresses paw-pinch
induced responses in absence of strychnine (STR). Following a 5-min
pretreatment with i.v. mexiletine, responses to calibrated bilateral hind paw-pinch
were determined (without STR). The stimulus evoked increase in M.AP.(A) and HR
(8) are shown. Each point represents the mean ± S.E.M. of 4-5 animals. Least
square regression lines and the corresponding 95% CI (dotted lines) are shown.
The horizontal solid lines indicate the mean ± 95% CI of all paw-pinch evoked
responses (N=16) before mexiletine.
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attempted to withdraw their hind paws during noxious stimulation but were
prevented from doing so to ensure a consistent noxious mechanical stimulation.
No withdrawal attempts were recorded in any of the rats receiving the 30 mglkg
dose. The EDS)'s of i.v. mexiletine against noxious pinch (without STR) and STR-
allodynia were very comparable and exhibited narrow 95% CI's (Table IV).
Table IV. EDsoS and 95% C.I. of t.v. Mexiletine
Response EDso(mglkg) 95%CI
·STR-allodynia:
MAP 15.70 8.67 - 28.42
Heart Rate 16.60 10.46 - 26.42
Duration of 13.83 9.58 -19.97
Withdrawal
Paw-pinch evoked responses:
MAP
Heart Rate
9.10
13.31
6.00 -13.82
9.66 -18.35
• STRwas injected 5 min after termination of the mexiletine infusion.
3.4 Effects ofAdenosine Agonists on Strychnine-allodynia
Pretreatment with Lt. CPA (0.001,0.05 and 0.1 I-Ig), 15 min before STR,
dose-dependently inhibited the HD-evoked rise in BP (Figure 12A), HR (Figure
128) and motor withdrawal(Figure 12C). Overall, Lt. CPA had no significant effect
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Figure 12. Intrathecal CPA dose-dependently suppresses intrathecal
strychnine(STR)-allodynia. Following a 15-min pretreatment with Lt. CPA,
responses to hair deflection (HD) were determined in the presence of Lt. STR (40
I-Ig). The HD-evoked increase in mean arterial pressure (M.A.P.; A), heart rate (8),
the duration for which withdrawal response could be evoked (C) and the 0"
synchrony in the EEG (D) are shown. Each point represents mean ± S.E.M. of 5-6
animals. Least squares regression lines and the corresponding 95% CI (dotted
lines) are shown. The horizontal solid lines and adjacent dotted lines indicate the
mean ±95% CI of all STR treatments (N=16) before CPA injection.
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on % synchrony of the EEG (Figure 12D). However, the data from two animals
receiving 0.05 ~g and one animal receiving 0.1 ~g were excluded from the final
results as the % synchrony exceeded the 60% cut off. The ED50 of Lt. CPA ranged
from 0.02 - 0.07 ~ (Table V). The inhibitcxy effect of Lt. CPA (0.2 ~g) was blocked
by pretreatment with the ~-antagonist, DPCPX (10 ~ i.t.; Figure 13). Interestingly,
i.t, DPCPX alone triggered mild spontaneous saatching and HD-evoked withdrawal
responses for approximately 5 - 10 minutes after injection in two animals (data not
shown).
I.l CGS also inhibited STR-induced allodynia in a dose-dependent manner
(Figure 14). However, doses of 2 - 5 IJQ were required to achieve inhibition
comparable to that of i.t, CPA at nearly 1J60the dose. The EDsoS of Lt. CGS ranged
from 2.7 - 3.1 ~g (Table V). This anti-allodynic effect was significantly blocked by
i.t, DPCPX (Figure 138). CGS had no detectable effect on level of anesthesia with
Table V. EDWS and 95% C.I. of CPA or CGS
Treatment Response ED50(~g) 95%CI
CPALt- MAP 0.07 0.02 -0.20
HR 0.06 0.01 -0.30
WD 0.02 0.01 - 0.09
CGS-Lt.- MAP 3.11 2.50 - 3.86
HR 2.75 2.09 - 3.61
WD 2.69 1.81 -3.98
- CPA and CGS were injected 15 min before STR.
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Figure 13. Inhibition of the anti-allodynic effect of CPA or CGS by
pretreatment with intrathecal DPCPX. DPCPX (10 ~g, Lt.) was administered 10
min before Lt. CPA (0.2 ~g) or CGS (5 ~). STR (40 ~g, i.t.) was given 15 min later
and responses to hair deflection (HD) were determined at 5-min intervals thereafter.
The effects of CPA (A) or CGS (B) (in absence and presence of DPCPX) on the
HD-evoked increase in mean arterial pressure (M.A.P.), heart rate, duration for
which motor withdrawal responses could be evoked (WO) and % synchrony (%
SYN) are shown. The solid bar represent the STR-control responses without any
drug treatment. Each bar represents mean ± SEM of 6 - 8 animals. (*p<0.05,
**p<0.01)
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Figure 14. Intrathecal CGS dose-dependently suppresses intrathecal
strychnine(STR)-allodynia. Following a 15-min pretreatment with Lt. CGS,
responses to hair deflection (HO) were determined in the presence of Lt. STR (40
IJg). The HO-evoked increase in mean arterial pressure (M.A.P.; A), heart rate (8).
the duration for which withdrawal response could be evoked (C) and the %
synchrony in the EEG (0) are shovm. Each point represents mean ± S.E.M. of 5~
animals . Least squares regression lines and the corresponding 95% CI (dotted
lines) are shown . The horizontal solid lines and adjacent dotted lines indicate the
mean ± 95% CI of all STR treatments (N=18) before CGS injection.
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the °Al synchrony remaining unchanged at all doses. At a dose of 5 I.Jg, Lt. CGS had
no antinociceptive effect against noxious bilateral hind paw pinch (n=2, data not
shown).
3.5 Effects of GABA Agonists on Strychnine-allodynia
I.t. muscimol (0.1, 0.5, 1 and 2.5 I.Jg), given 15 min before STR (40 I.Jg)
injection, dose dependently inhibited all indices of STR-allodynia (Figure 15). This
was accomplished without a change in the % synchrony of the EEG, which
remained below 60% cut off . The baseline arterial blood pressure and HR were
also unaffected by Lt. muscimol (data not shown). The EDso and 95% CI for Lt.
muscimol are summarised in Table VI.
Table VI. EDsqS and 95% C.I. ofMuscimo/*
Treatment
Muscimol Lt.
Response
MAP
HR
WD
0.51
0.0
0.44
95%CI
0.37 - 0.72
0.34 -0.74
0.32 - 0.61
• Muscimol was injected 15 min before STR
In contrast, baclofen (up to 10 1.J9, i.t.) failed to inhibit STR-induced allodynia
(Table VII). Rather there was a trend towards increased cardiovascular responses
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Figure 15. Intrathecal muscimol dose-dependently suppresses intrathecal
strychnine(STR)-allodynia. Following a 15-min pretreatment with Lt. muscimol,
responses to hair deflection (HD) were determined in the presence of Lt. STR (40
~g). The HD-evoked increase in mean arterial pressure (M.A.P.; A), heart rate (B),
the duration for which withdrawal response could be evoked (C) and the %
synchrony in the EEG (0) are shown . Each point represents mean ± S.E.M. of 5-7
animals. Least squares regression lines and the corresponding 95% CI (dotted
lines) are shown. The horizontal solid lines and adjacent dotted lines indicate the
mean ± 95% CI of all STR treatments (N=23-24) before muscimol injection.
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after Lt. baclofen. However, HD-evoked increase in MAP and HR following
baclofen (Table VII) was not significantly different from vehicle-control in STR-
treated rats. The withdrawal responses to HD were significantly inhibited by Lt.
baclofen (*p<0.01). Indeed,one rat receiving the 1 IJgdose, and all rats receiving
~5 IJ9exhibitedreversiblehind limb paralysis. Thus, HD-evoked motor withdrawal
responses were completely abated by high doses of baclofen at a time when
cardiovascular responses remained unaffected. The baseline arterial blood
pressure and HR were also unaffected by Lt. baclofen.
Table VII. Effect of baclofen on HD-evoked responses in STR-treated rats
Treatment MAP HR WD
(mmHg) (beats/min) (min)
Vehicle- 13.4 ± 1.6 20.7 ± 1.9 25 ± 2.0
control (14)
Baclofen*
1IJg (3) 22.8 ±4.9 33.3 ± 13.0 6.7 ± 3.3*
5IJg (4) 25.4 ± 5.0 40 ± 8.4 Absent
10 IJg(5) 22.3 ±4.8 29 ± 9.4 Absent
"Baclofen was injected 15-min before STR. Data are expressed as the mean ±
SEM of 3-14 animals (N values shown in the brackets) (*p<0.01). Mean arterial
pressure (MAP); heart rate (HR); withdrawal duration (WD).
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3.6 Effect of Milacemide on Strychnine-allodynia and Normal Nociception
Pretreatment with l.v milacemide (400 and 600 mg/kg) significantly inhibited
STR-allodynia (Figure 16 and 17). Maximal inhibition was observed 2-3 h after drug
administration (Figure 16). The duration of action ranged from 2 h for 400 mglkg
dose to 4 h for 600 mg/kg, and the % synchrony of the EEG was unchanged at all
doses throughout the experiment (Figure 160 and 170). The EOsosat the time of
maximum inhibition (i.e . 2 h after milacemide infusion) were approximately 400
mg/kg Lv. (Table VIII). Baseline BP and HR were dose-dependently depressed
during milacemide infusion (Le. before STR-allodynia). Baseline BP decreased by
15 (400 mglkg) to 25 mm Hg (600 mglkg) and HR decreased by 25 (400 mg/kg) to
50 bpm (600 rngIkg). For the 400 mglkg dose, BP and HR return to normal before
Lt. STR was injected (i.e, 1 h after milacemide infusion). At 600 mglkg, BP and HR
returned to normal 3 h after infusion, except in two animals where baseline HR and
BP remained depressed by approximately 10% and 8% of pre-injection values
throughout the experiment.
[Note: Oose-dependent depression of respiration was observed (visual
examination) during the first 15-20 min following the termination of milacemide
infusion).
In a separate group of animals, responses to noxious hind paw pinch
(without STR) and STR-allodynia were recorded every hour for 4 h after milacemide
infusion. At the time of maximum inhibition of STR-allodynia (2 h post-infusion),
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Figure 16. Intravenous milacemide exerts its maximum effect on intrathecal
strychnine(STR)-allodynia two hours after injection without affecting EEG
synchrony. Hair deflection (HO)~voked responses in the presence of Lt. STR (40
~g) were determined every hour for four hours after i.v. milacemide (400 mglkg;
approximateE0 50 value). Because of the short duration of anodynia «30min), Lt.
STR was repeated every hour . The maximum evoked increase in mean arterial
pressure (M.A.P.; A), heart rate (B), the duration for which a motor withdrawal
response could be evoked (C) and the % synchrony in the EEG (0) are shown.
Each point represents mean ± SEM of 6-8 animals. The horizontal dotted line is the
maximum evoked response to STR (mean ± SEM) in absence of any further
treatment (N=24). (*p<O .05, **p<O.01)
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Figure 17. Intravenous milacemide suppresses intrathecal strychnine(STR)-
allodynia in a dose- and time-dependent manner, without affecting EEG
synchrony. Hair deflection (HO)-evoked responses in the presence of Lt. STR (40
IJg) were measured every hour for four hours after Lv. milacemide (100, 400 and
600 mglkg). Oose-response curves for the dlange in mean arterial pressure (MAP;
A), heart rate (B), the duration for which withdrawal responses could be evoked (C)
and the % synchrony in the EEG (0) were determined 2h (e time of maximum
effect) and 4h (.&.) after injection. Each point represents the mean ± SEM of 6-8
animals. The horizontal dotted line is the maximum evoked response in STR-
treated rats (mean ± SEM) before milacemide (N=24) . (*p<0.05, **p<0.01)
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Figure 18. Milacemide (600mgl1cg, I.v.) significantly Inhibits Intrathecal
strychnine(STR)-allodynia but has no effect on normal mechanical
nockeptJon. Hair deflection (HD)~voked cardiovascular responses in STR-
treated rats, and responses to noxious paw-pinch (without STR) were determined
in the same animals two hours after intravenous milacemide (600mglkg) (time of
maximum inhibition of STR-allodynia). Noxious hind paw-pinch was applied
bilaterally using calibrated hemostats. The maximumevoked increase in mean
arterial pressure (MAP; A) and heart rate (8) are presented. The solid bars
represent the control responses to HD in STR-treated rats (STR + HD) or noxious
paw-pinch (withoutSTR). The hatched bars representthe corresponding response
following Lv. milacemide (Mil) . Each bar represents mean ± SEM of 4 animals.
(*p<O.05)
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responses evoked by noxious pinch were unaffected by milacemide (Figure 18).
Table VIII. ED5/) and 95" C.I. of milacemide
Treatment
Milacemide
Response
MAP
HR
WD
398.3
413 .2
404.5
95°kCI
292.5 - 542.3
195.6 - 872.6
301.1 - 543.4
calculated from dose-response curve determined 2h after
milacemide administration
3.6.1 Effect of Clorgyline and L-Deprenyl on the Action of Milacemide
The effect of i.v. milacemide (600 mglkg) on STR-allodynia was determined
in a separate group of rats pretreated with either l-deprenyl (specific MAO-8
inhibitor) or clorgyline (MAO-A inhibitor) . Clorgyline had no effect on milacemide
inhibition of STR-allodynia at either 2h or 4h based on HD-evoked changes in MAP
(Figure 18A), HR and withdrawal duration (data not shown). In contrast, l-deprenyl
significantly blocked the anti-allodynic effect of milacemide for up to 4 hours (Figure
18A). EEG synchrony was unaffected by any treatment, and c10rgyline or deprenyl
by themselves had no effect on STR-allodynia (data not shown). Tyramine (6.7
mglkg, i.v.) injected at the end of the experiment, induced an immediate and
sustained elevation in arterial blood pressure in c1orgyline-treatedrats (Figure 188).
Tyramine, up to 20 mglkg i.v., had no effect on blood pressure in l-deprenyl-treated
rats.
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Figure 19. The suppression of strychnine(STR)-allodynia by intravenous
milacem/de is blocked by I-deprenyl, but not clorgyline.
A Rats were pre-treatedwith c10rgyline (10 mglkg, i.p.) or l-deprenyl (3 mglkg, i.p.)
two hours before milacemide (600 mglkg, i.v.). Hair deflection (HD)-evoked
responses in the presence of Lt. STR (40 ~g) were determined every hour for four
hours after milacemide. Because of the short duration of allodynia «30 min), STR
was repeated every hour. The maximumevoked ina-ease in meanarterial pressure
(MAP), determined 2h and 4h after milacemide, is presented. The horizontal dotted
line represents the maximum response (mean ± SEM) in STR-treated rats in
absence of any other treatment (N=14). Each bar represents the mean ± SEM of
3-5 rats.(*p< 0.05, **p<0.01 )
B. Tyramine (6.7 mglkg, i.v.) triggered immediate and sustained increase in arterial
blood pressure in c1orgyline-treatedrats. Even at three times the dose (20 mglkg,
i.v.) tyramine had no effect in rats pre-treated with l-deprenyl.
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4 Discussion
4.1 Strychnine-allodynia
Hair deflection, applied to the dermatomes of rats pretreated with i.t. STR,
evoked physiological responses greater than those elicited by the chemical
nociceptive agent, mustard oil (see section 4.2). All STR-dependent responses
were: a) evoked (not spontaneous); b) observed without convulsions (no
generalized disinhibition of spinal neurons); c) only elicited by light brushing of the
hair at circumscribed sites corresponding to the spinal segments affected by i.t.
STR and d) completely reversible. These data indicate that robust allodynia can
be selectively induced with i.t. STR in animals whose somatosensory systems are
otherwise normal. They are also consistent with previous studies of STR-allodynia
(Seyeret aI., 1985, 1988; Yaksh, 1989; Sherman and Loomis, 1994, 1995), many
of which used phasic noxious stimuli for comparative purposes, demonstrating that
normally innocuous mechanical stimulation acquires nociceptive characteristics
during the pharmacological blockade of spinal glycine receptors. Indeed, there is
growing evidence that low threshold afferent input activates central nociceptive
pathways in the presence of i.t. STR (Milne et aI., 1996; Sherman et aI., 1996).
4.2 Effect of AP-7 on Strychnine-allodynia: role of NMDA receptors
STR-allodynia was dose-dependently inhibited by pretreatment with the
82
selective NMDA receptor antagonist, AP-7. This effect was not due to a general
depression of cardiovascular reflexes as Lt. AP-7 did not alter baseline
cardiovascular activity, nor did it inhibit the responses evoked by a phasic noxious
pinch. The lack of an effect on cortical EEG synchrony, the Lt. route of
administration and the correspondingly low ED50 values of AP-7 (0.4 - 1.7 ~g) are
all consistent with a spinal site of action in this study. Normally, spinal NMDA
receptors play little or no role in the synaptic transmission of low-threshold (A-fiber)
input (Urban et aI., 1994). Rather, they are known to mediate the phenomenon of
'wind up' (e.g. the temporal summation of long latency discharges from afferent C-
fibers and a characteristic feature of pain) in spinal neurons during repeated high-
threshold (C-fiber) stimulation (Dickenson and Sullivan, 1987). Indeed, NMDA
receptor antagonists have been shown to block 'wind up' in vivo without affecting
the neuronal responses to peripheral A-fiber stimulation (Price et aI., 1994). The
observation that STR-allodynia is highly sensitive to spinal NMDA receptor
blockade suggests that, in the presence of STR, low-threshold afferent input
acquires access to a central sensitization mechanism normally restricted to
repeated noxious stimulation.
That this sensitization process might be 'wind up' is supported by the
temporal pattern of BP and HR responses evoked by tonic brushing of the hair in
STR-treated rats. This consisted of a progressive increase in cardiovascular
responses during the stimulus train which persisted after the stimulus was
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discontinued. A similar pattern of HD-evoked neurochemical responses has been
observed in the locus coeruleus of STR-treated rats using differential normal pulse
voltammetry (Milne et aI., 1996). This pattern of evoked responses was matched
by the s.c. injection of mustard oil without STR. Mustard oil is a selective activator
of C-nociceptors (Woolf and Wall, 1986) that triggers 'wind up' in the rat; an effect
blocked by pretreatment with the NMDA antagonist, MK~1 (Woolf and Thompson,
1991). These results, and the recent report that rat dorsal hom neurons exhibit
'wind up' to repeated A-fiber activation following the iontophoretic application of
STR (Wilcox et aI., 1996), indicate that: a) normally innocuous mechanical stimuli
undergo nociceptive-like processing in the spinal cord of the rat during glycine
receptor blockade; and b) Lt. STR induces an abnormal pain state in experimental
animals consistent with the IASP definition of allodynia.
The present dose-response data for Lt. AP-7 are comparable to those of
other NMDA antagonists (MK-801 and AP-5) that inhibited tactile-evoked agitation
in conscious STR-treated rats (- ED60s= 3 ~g) (Yaksh, 1989), and in conscious
mice pretreated with Lt. prostaglandin E2 or F2a (EDso= 1.61.1g for AP-5, and 0.52
~g for MK-801; Minami et aI., 1994). The similarity of these data, determined in
lightly anesthetized and conscious rats, indicate that: a) the spinal pharmacology
of STR-allodynia is unaffected by controlled urethane anesthesia; and b)
experimental conditions mitigating many of the ethical issues arising from studies
of neuropathic pain in animals can be used reliably in the STR-model.
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Previous studies conducted in our laboratory showed that STR-allodynia is
inhibited by Lt. y-DGG and NBQX at doses that do not affect cardiovascular or
motor reflexes, or the plane of anesthesia (Sherman and Loomis, 1994, 1996). The
sensitivity of STR-allodynia to spinal NMDA and non-NMDA antagonists is in
agreement with our current understanding of sensory transmission at the level of
the spinal cord (Figure 20), and the hypothesis that allodynia arises from the
exaggerated depolarization of spinal neurons in pain pathways by low-threshold
afferent input. Hence, agents that negatively modulate such excessive excitatory
drive should block STR-allodynia.
4.3 Effect of Mexiletine on Strychnine-allodynia and Normal Nociception
Mexiletine, an orally active congener of lidocaine, is the most commonly
used local anesthetic for clinical allodynia (Hegarty and Portenoy, 1994) and should
be effective in any valid model of allodynia. In the present study, mexiletine dose-
dependently inhibited STR-allodynia and paw-pinch induced normal nociception
(without STR) as determined in the same experimental animals. Importantly,
mexiletine was equipotent in inhibiting the responses to normal and abnormal
nociceptive input (EDso's = 9.1-17 mglkg, i.v.). Below 30 mglkg, this effect was
achieved without a change in EEG synchrony (cortical activity reflecting the level
of anesthesia) and without affecting motor efferent pathways; the motor withdrawal
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Al3-fibers
Figure 20. Schematic diagram illustrating the postulated role of excitatory
amino acid (EAA)-receptor systems and neuromodulatory systems in the
spinal processing of low-threshold (AfJ) afferent input. Glutamate, released
from the central terminals of A~-fibers, combine with AMPAlkainate-receptors
(closed ovals) on both second order neurons and intemeurons in the dorsal hom.
The latter include excitatory (EAA) and inhibitory [GABA and glycine (Gly)]
substrates . Current evidence suggests that post-synaptic NMDA receptors (open
square) do not lie adjacent to primary afferent terminals but rather to those of
excitatory interneurons (Davies and Watkins, 1983; Evans and Long, 1989;
Schouenborg and Sjolund, 1986; Morris , 1989) . Thus, glutamate from EAA
intemeurons is thought to interact with NMDA receptors on the second order neuron
(Davies and Watkins, 1983; Evans and Long , 1989; Headley and Grillner, 1990;
Yoshimura and Nishi, 1995). The negative modulation of adenosine, GABA and Gly
on EM-mediated transmission is also indicated. For clarity , only the adenosine
(~) receptor (open circle) is shown. Probable sources of adenosine include low-
threshold primary afferents and intemeurons (Nagy and Daddona, 1985; Sawynok
and Sweeney, 1989) (not shown).
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responses to calibrated paw-pinch were preserved in mexiletine-treated rats. At 30
mg/kg or above, motor withdrawal responses were almost absent and EEG
synchrony was slightly but non-significantly increased , consistent with the report of
sedation, reduced locomotor activity and a slowed righting reflex in conscious rats
given a similar dose of mexiletine (Xu et aI., 1992).
The mexiletine doses used in the present study are similar to those reported
to inhibit allodynia-Iike symptoms after ischemic spinal cord injury in the rat (Xu et
aI., 1992). Spinal ischemia was induced photochemically by laser irradiation at mid-
thoracic region immediately after the l.v. administration of Erythrocin B. Allodynia-
like behaviours developed 6-8 months after irradiation and persisted for at least 4
months. Mexiletine (15 mglkg and 30 mglkg, i.p.) significantly inhibited allodynia
in these rats for 45-120 min; a duration of action similar to that observed in the STR
model. While a direct comparison of mexiletiine in injury vs non-injury (e.g. Lt. STR)
models of neuropathic pain will require more extensive and detailed experiments,
the present results suggest that chronic spinal cord injury yielding localized
allodynia does not display enhanced sensitivity to the anti-allodynic effect of
mexiletine when compared to the present pharmacological model. Strychnine-
allodynia may be useful for estimating the dose-response relationships of local
anesthetics in pathological central pain states, and for investigating their central
mechanism(s) of action.
Systemic local anesthetics, in doses ranging from 1-25 mglkg, do not block
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conduction in injured or non-injured peripheral nerve fibers (Woolf and Wiesenfeld-
Hallin, 1985; Chabal et aI., 1989; Tanelian and Maciver, 1991) . In the case of
mexiletine, i.v, doses of 10-15 mglkg yield peak serum/plasma concentrations of
1-5 ~gI~1 in the rat (Igwemezie et aI., 1991, 1992). These are within the range
reported for clinical analgesia and well below the concentration required to block
electrical conduction of peripheral M and C-fibers in vitro(>250 ~glml for lidocaine)
(Tanelian and Madver, 1991). Pain in peripheral neuropathic conditions has been
attributed to an abnormal afferent impulse barrage into the CNS from the trapped
end of the injured peripheral nerves (neuromas) and from the axotomised sensory
cell bodies in dorsal root ganglia (DRG). In turn, peripheral neuromas and their
associated DRG's are known to be sensitive targets for local anesthetics in cases
of experimental or dinical nerve injury (Wall and Devor, 1983; Chabal et aI., 1989;
Devor et aI. , 1992). For example, systemic local anesthetics suppress ectopic
neuroma and DRG discharge without blocking initiation or propagation of impulses
by electrical stimulation of sciatic nerve in rats with chronic sciatic nerve ligation
(Wall and Devor, 1983; Chabal et aI., 1989; Devor et aI., 1992). However, these
targets are not relevant to the STR model as no peripheral injury is induced. Thus,
there is no obvious peripheral site(s) of action of mexiletine in STR-treated rats.
In contrast, sub-anesthetic doses of local anesthetics are known to: a) block
conventional nociceptive transmission in the spinal cord of cats (Dejong et aI.,
1969; Dohi et aI., 1979), b) depress a C-fiber mediated polysynaptic reflex in the
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spinal cord of normal rats without blocking conduction in primary afferent fibers
(Woolf and Wiesenfeld-hallin, 1985), c) block C-fiber mediated 'wind up' in rats
(Fraser et aI., 1992) and d) inhibit both direct and synaptically driven NMDA- and
neurokinin-receptor mediated postsynaptic depolarization in the rat spinal neurons
(Nagy and Wooff, 1996). In the present study, i.v. mexiletine blocked the responses
of both noxious pinch and STR-allodynia with equal potency. These results suggest
that mexiletine inhibits both normal and abnormal nociception at a common central
site in the pain-signalling pathway. At the very least, a spinal site of action (e.g.,
spinal nociceptive neurons receiving convergent low- and high-threshold afferent
fiber input) is likely given the locus of action of Lt. STR in this model. Such a site
would explain the identical inhibitory potency and parallel dose-response curves of
i.v. mexiletine against noxious paw-pinch and STR-allodynia. However, supra-
spinal sites of action cannot be excluded. Electrophysiological experiments will be
required to test this hypothesis.
In summary, i.v. mexiletine inhibits STR-allodynia in the anesthetized rat at
doses that also block normal nociception. Sub-anesthetic doses of mexiletine can
suppress centrally induced allodynia in experimental animals that are devoid of
peripheral or central nerve injury. Mexiletine appears to have an important spinal
site of action in abnormal pain states.
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4.4 Effect of Adenosine Agonists on Strychnlne-allodynla: role of A f
receptors
The l.v. infusion of adenosine or the i.t. inject ion of adenosine analogue,
LPIA (~-agonist) has been shown to alleviate spontaneous pain, allodynia and pin-
prickhyperalgesia in cases of peripheral nerve injury (Sollevi et al., 1995; Karlsten
and Gordh, 1995; Belfrage et al., 1995). Consistent with this effect, CPA (an~­
selective agonist) and CGS (an ~-selective agonist) dose-dependently inhibited
STR-allodynia. However, the EDsoof Lt. CGS (2.7-3.1 I-Ig)was approximately 50
times greater than that of CPA (0.02 - 0.07 I-Ig) raising concerns about the
selectivity of CGS at spinal A1-receptors in the present study. This was confirmed
by the ability of a fixed dose of DPCPX to block the anti-allodynic effect of both CPA
and CGS. These data are in agreement with previous reports that the spinal
analgesic action of adenosine is selectively mediated by A1-receptors whereas the
motor dysfunction induced by spinal adenosine is mediated by ~-receptors
(Fastbom et al., 1990; Karlesten et al., 1991; Poon and Sawynok, 1995; Lee and
Yaksh, 1996). In this regard, it is important to note that motor withdrawal responses
evoked by noxious paw-pindl (without STR) persisted after the Lt. injection of CGS
(s 51J9) (data not shown). These results indicate that CGS did not adversely affect
the motor function in the STR-modeL
The EDsoS of CPA in the present study are comparable in order of magnitude
to those reported for RPIA and NECA in conscious STR-treated rats (EDsoS =0.1
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~g RPIA and NECA; Sosnowski and Yaksh, 1989) and for RPIA (ED so=0.2 ~g) in
rats with peripheral nerve injury (chronic ligation of L5 and L6 spinal nerves distal
to DRGs; Kim and Chung model) (Lee and Yaksh, 1996). A similar ED soof CGS (8
~g) was also reported in the spinal nerve ligation model (Lee and Yaksh, 1996).
Unlike the present study however, the anti-allodynic effect of CGS in the Kim and
Chung model, was not blocked by pretreatment with Lt. CPT (a selective A,-
receptor antagonist). There are several possible explanations for this difference.
First, the dose of CGS used in the injury model was rather high (21 ~g). Second,
10 ~g of DPCPX was used in the present study compared to 3 ~ of Lt. CPT.
Alternatively, nerve injury may trigger the expression of A;z-receptors through which
adenosine agonists exert their effects. This apparent difference in the
pharmacology of the STR- versus the spinal nerve ligation model could have
important implications for the investigation of adenosine agonist and needs to be
clarified in future experiments.
The absence of a significant effect on cortical EEG synchrony and the low
EDsovalues of CPA and CGS, support a spinal site of action in the present study.
Indeed the analgesic action of i.v. adenosine in patients with peripheral nerve injury
appears to be mediated by central adenosine receptors as the activation of
peripheral adenosine-receptors is known to result in painful symptoms (Belfrage et
aI., 1995). LPIA and NECA, given Lt. in doses ranging from 0.3 - 1 nmol (doses
inhibiting STR-allodynia in conscious rats), also produced dose-dependent
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antinociception in rats using the hot-plate and tail-fl ick tests (Sosnowski et aI.,
1989) . Similar doses of i.t. adenosine analogs also inhibited the scratching and
biting behaviour evoked by Lt. SP and NMDA; an effect antagonized by theophylline
(Delander and Wahl, 1988). These results indicate that the inhibitory effect of
adenosine is not restricted to abnormal pain states.
The mechanism(s) by which adenosine modulates sensory processing in the
spinal cord is unclear. However, the sensitivity of experimental models of allodynia
(both injury and non-injury) to Lt. EAA antagonists and adenosine A1-agonists
suggests a functional interaction between dorsal horn glutamate- and adenosine-
systems . One possibility is that A1-receptors, present on glutamate-containing
interneurons, inhibit glutamate release and attenuate EAA-mediated synaptic
transmission (see Figure 20). Indeed, recent electrophysiological recordings in
spinal cord slices of the hamster have shown that a principal effect of adenosine is
to inhibit interneuronal communication in the substantia gelatinosa (Li and Perl,
1994). Superfusion of adenosine (20-100 ~g) resulted in the inhibition of all
polysynaptic excitatory post-synaptic currents (EPSPs) evoked by dorsal root
stimulation. Moreover, binding studies have shown that A1- and ~-receptors are
located primarily on intrinsic neurons in the rat spinal cord (Choca et aI., 1988).
Although the identity of these neurons was not determined, they could include
glutamate-containing interneurons, second-order neurons, or both. A second
possibility is that ~-receptors are present on second order neurons which suppress
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glutamate-evoked depolarization following glutamate release from the central
terminals of primary afferent fibers and/or excitatory intemeurons. In either case,
these postsynaptic mechanismswould counteract the exaggerated excitatory input
from low threshold afferent fibers during spinal glycinergic disinhibition.
The pre-synaptic effects of adenosine are suggested by the reports
demonstrating the inhibition of glutamate release in vitro using brain slice
preparations from the hippocampus and dentate gyrus of the rat (Fastboom and
Freedlom, 1985; Dolphine and Prestwich, 1985). This effect was abolished by 8-
phenyltheophylline (10 1JOl) suggesting that ~-receptors were involved. While a
presynaptic effect on primary afferent terminals has been proposed (Li and Perl
1994), immunocytochemical studies failed to detect either ~ or ~ receptor-like
immunoreactivity on these spinal substrates (Choca et aI., 1988). Thus, current
evidence supports a postsynaptic inhibitory effect of adenosine (Delander and Wahl
1988; Li and Perl, 1994), presumably on spinal substrates receiving low- and/or
rugh-threshold afferent input. Regardless of the exact mechanism(s), A1-receptors
appear to be strategically located in the spinal cord to modulate somatosensory
input.
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4.5 Effect of GABA Agonists on Strychnine-allodynia: role of GABAA
receptors
The results of the present study indicate STR-allodynia is selectively
modulated by spinal GABAA receptors. Thus, the Lt. muscimol dose-dependently
inhibited STR-allodynia in lightly anesthetized rats. Such an effect on STR-allodynia
has not been shown previously but is consistent with reports of allodynia in rats and
mice following Lt. bicuculline, a selective GABAA antagonist (Yaksh, 1989; Onaka
et aI., 1996; unpublished results). That this represented a selective spinal site of
action is indicated by the lack of the effect on cortical EEG synchrony and the low
EDsovalues (0.4 - 0.5 jJg). In contrast, i.t. baclofen failed to suppress the abnormal
responses to HD in presence of STR, even at doses which produced pronounced
motor dysfunction. These data are in agreement with a previous report
demonstrating the lack of effect of baclofen against STR-allodynia in conscious rats
(Yaksh, 1989) and electrophysiological data demonstrating the lack of effect of
intra-arterial CGP 35348 (60 mglkg) on the spontaneous activity of hamstring flexor
a-motoneurons, touch evoked-responses or touch threshold in the spinal cord of
the rat (Sivilotti and Woolf, 1994) .
The present results are not surprising given the fact that a) GABAA and
glycine receptors independently open chloride channels to hyperpolarize neurons
(Bormann et aI., 1987; Cohen et aI., 1989); b) GABAA and glycine receptors are co-
contained on the same postsynaptic membrane in the spinal dorsal horn (Todd et
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al., 1996) consistent with the co-localization of glycine and GABA in the same
presynaptic axons (Todd et aI., 1996); and c) glycine immunoreactivity is virtually
restricted to neurons that also exhibit GABA immunoreactivity in the laminae I-III of
the dorsal hom (Todd, 1990; Mitchell et aI., 1993). Glycine intemeurons receive
a major monosynaptic input from large diameter myelinated primary afferents in
laminae II and III. These anatomical studies provide evidence for the neuronal
circuitry by which glycine and GABA might normally modulate non-nociceptive
transmission. They also suggest that GABA and glycine, co-released from the same
intemeurons might effect discrete but complementary inhibition of relevant spinal
neurons. Indeed, electrophysiological studies using spinal cord slices from the rat
and cat have shown that GABAA- and glycine-mediated inhibition have a distinct
time-course (Game and Lodge, 1975; Baba et aI., 1994; Yoshimura and Nishi,
1995). The long and short IPSP, generated in substantia gelatinosa by stimulation
of A6-fibers was blocked by bicuculline and STR, respectively (Yoshimura and
Nishi, 1995). The bicuculline-sensitive IPSP was up to 3 times slower than that of
STR-sensitive inhibition reflecting the different kinetics of GABAA- and glycine-
receptors, or a different time course of the neurotransmitter uptake . It has been
suggested that the STR sensitive IPSP may be important in limiting the firing of the
neurons and curtailing the amplitude and the ability of the EPSP to generate an
action potential. In contrast, the bicuculline sensitive IPSP which develops more
slowly and has a longer duration may be effective in preventing longer lasting
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repetitive activation (Yoshimura and Nishi , 1995) . While the exact role and
significance of glycine- and GABA-inhibition remains to be determined, the
apparently complementary effects of glycine and GABA on somatosensory input are
consistent with the inhibition of STR-allodynia by Lt. GABA" agonists. Indeed, one
would expect glycine or GABA (acting at GABA,,-receptors), to attenuate the
exaggerated firing evoked by AJ3-input in presence of STR.
The role of GABAe-receptors in the modulation of low-threshold afferent
transmission is controversial. The failure of i.t. baclofen to inhibit STR-allodynia in
the present experiment suggests that, in absence of nerve injury, spinal GABAe-
receptors do not contribute significantly to such modulation. However, l.p. baclofen
(but not muscimol) inhibited touch-evoked allodynia following focal spinal cord
ischemia in the rat (Hao et aI., 1992); an effect attributed to the activation of
GABAe-receptors present on the spinal terminals of AJ3-fibers. Baclofen also
reduced the hypersensitivity of spinal WDR neurons to low-intensity mechanical
and electrical stimulation in rats with spinal cord ischemia (Hao et aI., 1992). The
ability of baclofen to effect such changes in this ischemic model may represent an
up-regulation of GABAe-receptors in response to central injury and/or altered
synaptic connections. Although GABAg binding sites have been reported on the
terminals of large diameter primary afferent fibers in lamina IV of normal rats (Price
et aI., 1987), GABAg-receptors may not become functionally active until after central
nerve injury. These data also suggest that the STR model is relevant for
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investigating the somatosensory processing but may not reflect upon the altered
pharmacology induced by nerve injury.
4.6 Effect of Afilacemide on Strychnine-allodynia: role of glycine receptors
Systemic administration of the glycine prodrug, milacemide dose-
dependently inhibited STR-allodynia for up to 4 hours. The time course of this effect
corresponds to the ina-ease in glycine concentration in the CSF of rats treated with
milacemide (400 mglkg, i.p.) (Semba et I., 1993). The peak inhibition of STR-
allodynia and the maximum increase in [glycine1csF were achieved 2-3 h after
mialcemide administration. That the blockade of STR-allodynia was due to glycine
and not milacemide itself was confirmed by the dependency of this effect on MAO-
B. Thus, pre-treatment with l-deprenyl, but not clorgyline, significantly blocked the
anti-allodynic effect of milacemide .
There is strong pharmacokinetic and biochemical evidence that serum
milacemide rapidly enters and equilibrates in the. CNS compartment where it is
metabolized by MAO-B (Semba and Patsalos , 1993; Semba et aI., 1993). In fact,
over 90% of the milacemide dose is metabolized by MAO-B to glycinamide and
finally glycine (Figure 3). The remaining 10% is metabolized by different routes
depending on the species. In support of this metabolic route, and consistent with
the results of the present study, pretreatment with l-deprenyl (2 mglkg, i.p.)
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inhibited: a) the conversion of milacemide to glycine in vivo; and b) the ability of
milacemide to increase the seizure threshold induced by hyperbaric oxygen in rats
(Yadium et al., 1988). Indeed, pretreatment with l-deprenyl (2 mglkg, i.p.) almost
completely blocked the formation of glycinamide, and increased milacemide
accumulation in rat CSF (Semba et al., 1993). Pretreatment with clorgyline (5
mgIkg, l.p.)yielded only a moderate decrease in glycinamide concentration (Semba
et al., 1993).
The ability of glycine , derived from milacemide through the action of MAO-B,
to inhibit STR-allodynia is supported by previous work in our laboratory. Glycine
or betaine (N,N,N-trimethyl glycine) injected directly into the spinal subarachnoid
spaceof the rat, dose-dependently inhibited STR-allodynia (Sherman and Loomis,
1995). Moreover, i.v. milacemide had no significant effect on normal nociception
(phasic noxious paw-pinch without STR) in the present study. The persistence of
these noxious-evoked responses indicates that cardiovascular efferent fibers were
unaffected by i.v, milacemide, and that the suppresion of cardiovascular responses
to HD in the STR model represented a true anti-allodynic effect. These results also
support the hypothesis that glycine is a selective modulator of non-noxious
somatosensory input in the spinal cord of the rat.
In addition to the STR-sensitive glycine receptor, glycine is also known to
bind to a STR-insensitive co-agonist site on the NMDA-receptor complex. In the
case of the latter , glycine augments the excitatory effects of NMDA (Rosse et al.,
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1991). Considering the sensitivity of STR-allodynia to NMDA antagonists (see
section 4.2), the potentiation ci NMDA-receptor mediated depolarization by glycine
would be expected to worsen the allodynia. We observed no evidence of this in the
present study, but subtle changes in NMDA neurotransmission are unlikely to be
detected using cardiovasa.darand motor end-points. Such an outcome will require
more sensitive electrophysiological techniques. Nevertheless, the primary effect
of milacemide in STR-allodynia was inhibitory. In this regard, it has been suggested
that the accumulation of unmetabolized milacemide following high-dose
administration may antagonize the possible enhancement of NMDA-mediated
transmission by glycine (Rosse et aI., 1991).
Besides glycine, systemic milacemide (400 mglkg, i.p.) is known to increase
the concentration of serine and taurine in rat CSF by 20-25% and to decrease
alanine concentration by an equal percentage (Samba and Patsalos, 1993). GABA
and glutamine concentrations in the CSF were unchanged. The relevance of the
decrease in alanine concentration, if any,. is not yet known, but a significant
increase in taurine and serine concentration could be of importance to the effed of
milacemide in the STR model. Taurine, alanine, and serine are agonists at the
STR-sensitive glycine receptor having the following order of potency: glycine »~
alanine> taurine> > L-alanine > L-serine (Pan and Slaughter, 1995). Taurine is
also shown to ad on GABA,. receptors in the cerebral cortex ( Pan and Slaughter,
1995) but sud1 effect has notyet been shown in the spinal cord. The comparatively
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small increase in serine and taurine concentration (20-25% versus 75-80°", for
glycine), their lower affinity for the glycine receptor compared to glycine, and the
lack of evidence for distinct taurine and serine receptors suggest that the reported
changes in serineand taurine concentrations are unlikely to playa major role in the
anti-allodynic effect of milacemide. Nevertheless, their contribution cannot be
excluded at the present time.
Like l-deprenyl, milacemide is also a selective inhibitor of MAO-B, both in
vivo and in vitro (de Varebeke et aI., 1989; O'Brien et aI., 1994). Ten hours after
a single injection of milacemide (500 mglkg, i.p.) to the rat, the MAO-B activity in the
brain was reduced to approximately 40% of control. This activity was significantly
but incompletely recovered (approximately 75% of control) 40 hours after
milacemide administration. As a result of this effect on MAO-B, milacemide is self-
limiting during long term therapy. In the present study, only one dose of milacemide
was injected per animal to avoid the complications of residual enzyme inhibition and
thus a decrease in glycine production with subsequent doses. The eventual
inhibition of MAO-B by milacemide, and thus the possible progressive decrease in
the yield of glycine, may explain the use of such high doses of the prodrug in vivo
to achieve a pharmacological effect. Clearly, glycine prodrugs that lack such
enzyme inhibitory activity would be preferable for chronic use . While the present
study investigated the acute effects of milacemide in the STR model, these data
indicate the effectiveness of a systemically administered glycine prodrug in
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attenuating abnonnal sensitivity to low-threshold afferent input arising in the spinal
cord. To the extent that the loss of spinal glycinergic modulation might underlie
clinical allodynia, this pharmacological approach may be worth investigating,
particularly in patients who respond poorly to current therapy.
4.7 Future Directions
From an experimental point of view, the STR model affords some unique
advantages. First, STR-allodynia is reversible, making it possible to test drugs
under normal and abnormal (Lt. strychnine) nociceptive conditions in the same
animal. Second, it is highly reproducible (with repeated STR injection) allowing for
quantitative dose-response analysis (as indicated by the narrow 95% confidence
intervals in Tables III-VI, VIII). Finally, it is centrally induced, of known cause, and
achieved without injury to the peripheral or central nervous system, thereby
allowing certain conclusions to be made about the site, and to a lesser extent, the
mechanismsof drug action. However, the experiments that can be undertaken are
limited by the short duration of allodynia (peak effect is approximately 5 min after
STR injection; duration of 20-30 min). It is not possible to test the chronic effects
of glycinergic dysfunction using this model or the long term effectiveness of
pharmacological interventions known to inhibit STR-allodynia. Although the
pharmacology of STR-allodynia mimics, qualitatively, that observed in humans, it
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is not yet known whether the loss of glycinergic modulation underlies clinical
allodynia. Therefore, further investigation is required to test this hypothesis. One
possible way to induce a more prolonged yet reversible glycinergic dysfunction is
to -knock our spinal glycine receptors using antisense oligonucleotides. Such a
model might prove useful to supplement and extend the information determined in
the STR model.
The interaction between glycine and GABA in modulating low-threshold
afferen input, and the consequences d simultaneous dysfunction of both inhibitory
inputs in the developmentof allodynia have not yet been investigated. Given their
known co-Iocalization in spinal intemeurons, a more realistic model of spinal
disinhibition and allodynia must take into account, the complementary role played
by these inhibitoryamino acids. This could be achieved initially by co-administering
i.t. GABA and glycine-antagonists . However, longer term spinal glycinergic and
GABAergic dysfunction would require a different approach, possibly using
appropriate antisense oligoneuclotides.
4.7 Summary
Increased spinal glutamatergic tone has been shown to yield a state of
facilitated transmission of both low- and high-intensity stimuli (Dougherty et aI.,
1992). Of the glutamate receptor family, spinal NMDA-receptors are especially
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important as these receptors mediate long lasting depolarisation including the
phenomenon of 'wind up'. Such augmentation appears to be an important spinal
mechanism underlying the condition of allodynia and hyperalgesia (Yaksh and
Malmberg, 1994). Moreover, interventions that counteract such exaggerated
neurotransmission in the spinal cord should alleviate these sensory events and
provide pain relief. The present research demonstrates that the abnormal
responses evoked by input from low-threshold mechanoreceptive afferents in
presence of spinal STR are indeed sensitive to NMDA-receptor blockade, to Lt.
glycine-, GABA- and ac:tenosine-agonists and to sub-anesthetic doses of mexiletine.
The evidence obtained in this study supports the following conclusions:
Glycine is a selective modulator of non-noxious somatosensory input in the
spinal cord of the rat.
In the presence of Lt. STR, low threshold afferent input accesses a spinal
sensitisation mechanism normally activated by nociceptive fibers.
3 Mexiletine inhibits both abnormal (STR-allodynia) and normal nociception at
a common site, most likely dorsal horn cells receiving convergent A~- and
C-fiber input.
4 The recruitment of neuromodulatory systems involving spinal adenosine A1
and GABAA receptors blocks the abnormal sensory responses of allodynia
following glycinoceptor blockade in the spinal cord.
Increasing central glycine concentration by means of a systemic glycine
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prodrug (milacemide) is effective in blocking STR-allodynia.
6 The spinal pharmacology of STR-allodynia is distinct from that of normal
nociception,and is similar to that currently understood in clinical allodynia.
7 STR-allodynia is a useful. acute, non-injurymodelfor the investigation of this
abnormal pain state.
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